10-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K / A

Amendment No.2

(Mark One)

[X]

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.  For the Fiscal Year Ended  December 31, 2014

[   ]

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from ________ to ________

TECHNOLOGY APPLICATIONS INTERNATIONAL CORPORATION

(Exact name of registrant as specified in its charter)

Florida	0-53698	27-1116025
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)
	Chase Bank Building 150 SE 2nd Ave, Suite 403 Miami, Florida 33131  (Address of principal executive offices)
	(800) 670-0448 (Registrant’s Telephone Number)
	Copy of all Communications to: Law Office of Andrew Coldicutt 1220 Rosecrans Street, PMB 258 San Diego, CA 92106 Phone: 619-228-4970 Email: Info@ColdicuttLaw.com

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes [   ]   No [X]

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes [   ]   No [X]

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes [X]   No [   ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X]   No [   ]

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  [   ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[   ]	Accelerated filer	[   ]
Non-accelerated filer	[   ] (Do not check if a smaller reporting company)	Smaller reporting company	[X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [   ] No [X]

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 30, 2014 was $18,380,871 based upon the price ($1.40) at which the common stock was last sold as of the last business day of the most recently completed second fiscal quarter, multiplied by the approximate number of shares of common stock held by persons other than executive officers, directors and five percent stockholders of the registrant without conceding that any such person is an “affiliate” of the registrant for purposes of the federal securities laws. Our common stock is not traded in the over-the-counter market and quoted on the Over-The-Counter Bulletin Board.

As of April 15, 2015, there were 50,473,093 shares of the registrant’s $0.001 par value common stock issued and outstanding.

Documents incorporated by reference: None

2

_________________________

EXPLANATORY NOTE

_________________________

This Amendment No. 2 (this "Amendment") to the Annual Report on Form 10-K of Technology Applications International Corporation (the "Company") for the year ended December 31, 2014, originally filed with the U.S. Securities and Exchange Commission (the "SEC") on April 15, 2015, (the "Original Filing"), is being filed to update the Auditor Consent letter and to correct the Security Ownership of Management table.

Except as described above, this Amendment does not modify or update the disclosures presented in, or exhibits to, the Original Filing in any way.  This Amendment speaks as of the date of the Original Filing and does not reflect events occurring after the filing of the Original Filing.  Accordingly, this Amendment should be read in conjunction with the Original Filing, as well as any other filings made by the Company with the SEC pursuant to Section 13(a) or 15(d) of Securities Exchange Act of 1934, as amended, subsequent to the filing of the Original Filing.

3

Table of Contents

		Page
	PART I	5
Item 1	Business	5
Item 1A	Risk Factors	13
Item 1B	Unresolved Staff Comments	19
Item 2	Properties	19
Item 3	Legal Proceedings	19
Item 4	Mine Safety	19
	PART II	20
Item 5	Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	20
Item 6	Selected Financial Data	22
Item 7	Management's Discussion and Analysis of Financial Condition and Results of Operations	23
Item 7A	Quantitative and Qualitative Disclosures about Market Risk	25
Item 8	Financial Statements and Supplementary Data	F-1
Item 9	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	26
Item 9A	Controls and Procedures	26
Item 9B	Other Information	27
	PART III	29
Item 10	Directors and Executive Officers and Corporate Governance	29
Item 11	Executive Compensation	32
Item 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	33
Item 13	Certain Relationships and Related Transactions	34
Item 14	Principal Accountant Fees and Services	35
	PART IV	36
Item 15	Exhibits	36

4

FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements are not historical facts but rather are based on current expectations, estimates and projections. We may use words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “foresee,” “estimate” and variations of these words and similar expressions to identify forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted. These risks and uncertainties include the following:

·

The availability and adequacy of our cash flow to meet our requirements;

·

Economic, competitive, demographic, business and other conditions in our local and regional markets;

·

Changes or developments in laws, regulations or taxes in our industry;

·

Actions taken or omitted to be taken by third parties including our suppliers and competitors, as well as legislative, regulatory, judicial and other governmental authorities;

·

Competition in our industry;

·

The loss of or failure to obtain any license or permit necessary or desirable in the operation of our business;

·

Changes in our business strategy, capital improvements or development plans;

·

The availability of additional capital to support capital improvements and development; and

·

Other risks identified in this report and in our other filings with the Securities and Exchange Commission or the SEC.

This report should be read completely and with the understanding that actual future results may be materially different from what we expect. The forward looking statements included in this report are made as of the date of this report and should be evaluated with consideration of any changes occurring after the date of this Report. We will not update forward-looking statements even though our situation may change in the future and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Use of Term

Except as otherwise indicated by the context, references in this report to “Company”, “TAIC,” “TCHA,” “NUUU,” “Technology Applications,” “Rejuvel Int’l, Inc.,” “NueEarth, Inc.,” “Rejuvel,” “we,” “us,” and “our” are references to Technology Applications International Corporation. All references to “USD” or United States Dollars refer to the legal currency of the United States of America.

5

PART I

ITEM 1. BUSINESS

Corporate History

The Company was incorporated as Raj Ventures, Inc., in the State of Florida on October 14, 2009, to effect a merger, exchange of capital stock, asset acquisition or other similar business combination, including being used as a vehicle for a reverse merger acquisition with an operating or development stage business which desired to utilize its status as a reporting corporation under the Exchange Act.

On April 12, 2010, one hundred percent of the issued and outstanding common stock of the Company was transferred and sold to Raj Ventures Funding, Inc., a company owned and controlled by Charles J. Scimeca, which resulted in a change in control of the Company. Ms. Colleen Foyo, Raj Ventures, Inc. sole officer and director resigned on April 12, 2010, and Mr. Scimeca replaced her, as the President, Secretary and Treasurer and sole director of the Company and he continues to serve in such capacity.

On August 26, 2010, the Company, completed the purchase of a semi-trailer mountable mobile electron beam accelerator unit contained therein (collectively, the “e-beam”) from High Voltage Environmental Applications, a Florida corporation (“HVEA”), in exchange for Ten Dollars ($10) and the issuance of one hundred thousand (100,000) shares of common stock of the Company to HVEA, which was payable as purchase price consideration for the transaction.

On April 12, 2011, the Company filed Amended and Restated Articles of Incorporation of the Company with the Secretary of State of Florida and changed the corporate name from “Raj Ventures, Inc.” to “Technology Applications International Corporation”. The Company also increased the authorized capital from 100 million shares of common stock to 350 million shares of capital stock, of which 300 million shares are common stock, par value $.001 per share, and 50 million shares are preferred stock, par value $.001 per share (“Preferred Stock”). The Company also adopted Amended and Restated Bylaws of the Company on the same date.

On April 12, 2011, the Company launched its new business NueEarth, Inc., which is a wholly-owned subsidiary of TAIC with the plan to develop, build and sell environmental solutions for the treatment of municipal and industrial wastewater and sludge, as well as cosmetic cross-linking, medical waste disinfecting and many other possible applications. The Company owns and intends to operate the mobile electron beam particle accelerator unit installed in a semi-tractor trailer, which it plans to use for the commencement of operations and making sales presentations to prospective customers throughout the United States, and to other countries.

On August 9, 2011, the Company founded a wholly-owned subsidiary Rejuvel Int’l, Inc., that distributes markets and sells a line of molecularly enhanced skin cream products, under the brand name Rejuvel.  On December, 29, 2011, and amended on January 23, 2012, May 7, 2012, and December 13, 2012, the Company entered into a distribution agreement with Regenetech, Inc., whereby, Rejuvel shall act as a distributor for a series of cosmetics created in a rotatable perfused time varying electromagnetic force bioreactor developed and patented by the National Aeronautics and Space Administration (“NASA”) and Regenetech, Inc., then manufactured and sold by Regenetech.

On September 30, 2013, the Company entered into a partially exclusive Co-License Agreement (the “License Agreement”) by and amongst the National Aeronautics and Space Administration, an agency of the United States (“N.A.S.A.”) and the Administrators of the Tulane Educational Fund (“Tulane University”) for the use of U.S. Patent No. 6,730,498 B1, an invention entitled “Production of Functional Proteins: Balance of Shear Stress and Gravity,” which was issued on May 4, 2004 (the “Patent”). We currently use the Patent process to develop our anti-aging skin creams and shampoos. The License Agreement permits the Company to use the Patent as well as the name N.A.S.A., with its products, as per the terms of the License Agreement.

On October 3, 2013, the Company terminated its distribution agreement (“Distribution Agreement”) by and between the Company and Regenetech, Inc., a Texas corporation, pursuant to the termination clauses contained within the Distribution Agreement as filed as Exhibit 10.7 as part of our Form S-1 Registration statement on December 27, 2012.  Regenetech, Inc., was in a material breach of contract of the Distribution Agreement, because Regenetech, Inc., failed to upkeep its license requirements with N.A.S.A. and Tulane University in order to maintain

6

the license in good standing.  Due to the material breach of contract by Regenetech, Inc., the termination of the Distribution Agreement does not contain any early termination penalties to the Company.

The Company

The Company is engaged in the production, distribution, marketing and sale of skin care products, as well as the marketing and sale of environment management solutions. It is focused on distributing a cosmetic line produced by the Company, under our own brand name, further developing and manufacturing our own line of technologically advanced skin care products and is planning on developing the e-beam technology for uses in the cosmetic industry. The Company also provides environmental management solutions that use electron particle accelerator technology. The Company maintains a website at www.tapplic.com and www.Rejuvel.com, in order to help provide more information to its potential customers. The company structure is set forth in the following chart:

	TECHNOLOGY APPLICATIONS INTERNATIONAL CORPORATION a Florida Corporation
Rejuvel Int’l, Inc. a Florida Corporation (100% owned subsidiary)		NueEarth, Inc. a Florida Corporation (100% owned subsidiary)

Corporate Strategy

The Company’s business strategy is aimed at building value through positioning each of the operating subsidiaries as a niche provider of technologically advanced products or services within its specific area of operation. The Company anticipates updating and refining the business strategy as new opportunities present themselves. In general, the component functions of the business model are to:

•   incrementally invest, market, and refine the acquired technology;

•   concentrate initial sales efforts on focused market entry opportunities; and

•   increase sales to a level that establishes market acceptance, as determined by the Company’s management.

Products

Rejuvel Int’l, Inc.

Through Rejuvel Int’l, Inc., the Company is currently distributing a line of technologically advanced skin care products, produced and developed by the Company. On July 27, 2011, it commenced providing to the marketplace its first product, the Rejuvel skin cream, and had generated revenues in the amount of $94,096 as of the year ended December 31, 2014. During 2012, the Company decided to rebrand our skin cream from “Renuéll™” to “ReJuvel”, to better relate to our potential markets, and on September 11, 2014 we changed the name of our subsidiary to Rejuvel Int’l, Inc.. Our skin cream product is a high quality cosmetic product that uses 3 dimensional biomolecules created in simulated microgravity that is formulated with a branded compound which is a breakthrough facial repair cream that allows skin cell expansion, and is enhanced using National Aeronautics and Space Administration (“N.A.S.A.”) technology to create a skin care product that promotes the appearance of age defying skin.  Renuèll is recognized by the Space Foundation for their use of products and processes designed by the space industry.

The Space Foundation is an international nonprofit organization and the foremost advocate for all sectors of the space industry - civil, commercial, national security, new space entrepreneurship, and finance. A leader in space awareness activities, major industry events, and educational enterprises, the Space Foundation is based in Colorado Springs, Colo., has an office in Washington, D.C., and has a field office in Houston, Texas. The Space Foundation employs a variety of programs and initiatives that educate and raise awareness about the importance and impact of the space industry.

7

In order for a company to be certified by the Space Foundation it must be a product or service that directly results from Space technology or space program development such that the product exists because of advances in space technology. Examples of certified space technologies include Fisher Space Pens, GPS, and Tempur-Pedic foam mattresses.  The Space Foundation has also officially certified Rejuvel as a Certified product that is produced using N.A.S.A.’s technology.  

Neither the Food and Drug Administration (“FDA”) nor any other regulatory authority or similar regulator has approved the Rejuvel™ skin cream product.

On December 29, 2011, and then Amended on January 23, 2012, May 7, 2012 and December 13, 2012, the Company, through its wholly-owned subsidiary, Rejuvel Int’l Inc., a Florida corporation (“Rejuvel”) entered into that certain distribution agreement (the “Distribution Agreement”) with Regenetech, Inc., a Texas corporation (“RGT”), see section “Distribution Agreement” for further details of the agreement. Pursuant to the terms and conditions of the Distribution Agreement, Rejuvel shall act as an exclusive distributor for a series of cosmetics created in a rotatable perfused time varying electromagnetic force bioreactor developed, manufactured and sold by RGT.

On September 30, 2013, the Company entered into a partially exclusive Co-License Agreement (the “License Agreement”) by and amongst the National Aeronautics and Space Administration, an agency of the United States (“N.A.S.A.”) and the Administrators of the Tulane Educational Fund (“Tulane University”) for the use of U.S. Patent No. 6,730,498 B1, an invention entitled “Production of Functional Proteins: Balance of Shear Stress and Gravity,” which was issued on May 4, 2004 (the “Patent”). We currently use the Patent process to develop our anti-aging skin creams and shampoos. The License Agreement permits the Company to use the Patent as well as the name N.A.S.A., with its products, as per the terms of the License Agreement.

The rotatable perfused time varying electromagnetic force bioreactor is operated by the National Aeronautics and Space Administration. In use, the rotatable perfused time varying electromagnetic force bioreactor supplies a time varying electromagnetic force to the rotatable perfusable culture chamber of the rotatable perfused time varying electromagnetic force bioreactor to expand cells contained therein.  Lab-grown cell cultures tend to be small, flat and two-dimensional, unlike normal tissues in the body. However, tissues grown in the bioreactor are larger and three-dimensional, with structural and chemical characteristics similar to normal tissue. The bioreactor has no internal moving parts, which minimizes forces that might damage the delicate cell cultures.

Cells cultured on Earth (left) typically settle quickly on the bottom of culture vessels due to gravity. In microgravity (right), cells remain suspended and aggregate to form three-dimensional tissue. The N.A.S.A. patented Bioreactor provides a low turbulence culture environment which promotes the formation of large, three-dimensional cell clusters. The bioreactor is rotated to provide gentle mixing of fresh and spent nutrient without inducing shear forces that would damage the cells. Due to their high level of cellular organization and specialization, samples constructed in the bioreactor more closely resemble the original tissue found in the body.

These expanded cells when placed on the skin in cream form help repair, hydrate and expand the cells in the skin, thereby, giving a rejuvenated and fresher appearance to a person’s skin. Rejuvel has licensed the patented process from N.A.S.A; Regenetech and Rejuvel are the only cosmetic companies that use this process and to be endorsed by the Space Foundation.

8

NueEarth, Inc.

Through NueEarth, Inc., the Company plans to develop, build and sell environmental solutions for the treatment of drinking water, municipal and industrial wastewater, sludge and produced water from oil and gas fracturing activities utilizing an electron particle accelerator technology combined with conventional methods. The e-beam works by using an electron beam particle accelerator unit that creates high energy electrons which produce free radicals in the waste water leading to decomposition of organic compounds (pollutants). We plan to develop various applications to use e beam technology for removal of pollutants from wastewater, drinking water, municipal sludge and fracking liquids.

The e-beam has the dual ability to also enhance cosmetic products and has the capacity to eliminate organic compounds present in water from parts per million concentrations to non-detectable concentrations in most cases. The Company owns and operates a mobile e-beam unit installed on a trailer that can be attached to a semi-truck, which it intends to use for the commencement of operations and making sales presentations and focusing on pilot opportunities with prospective customers.

On July 25, 2014, Technology Applications International Corporation and its wholly-owned subsidiary Renuell Int’l, Inc., Florida corporations (the “Company”) entered into an exclusive License Agreement (the “License Agreement”) by and between the National Aeronautics and Space Administration, an agency of the United States (“N.A.S.A.”) for the use of U.S. Patent No.’s 6,485,963 B1, an invention entitled “Growth Stimulation Of Biological Cells and Tissue By Electromagnetic Fields and Uses Thereof” which was filed on June 2, 2000, and U.S. Patent No. 6,673,597 B2, for an invention entitled “Growth Stimulation of Biological Cells and Tissue By Electromagnetic Fields and Uses Thereof: which was filed on February 28, 2001 (the “Patents”). We currently use the Patents process to develop our anti-aging skin creams and shampoos. The License Agreement permits the Company to use the Patents as well as the name N.A.S.A., with its products, as per the terms of the License Agreement.

In consideration of the grant of the License Agreement, the Company will pay a 3% royalty to N.A.S.A. on the gross sales of any royalty-base products. The License agreement further requires the Company to remit to N.A.S.A. a non-refundable license fee in the amount of Fifteen Thousand Dollars ($15,000) upon the execution of the License Agreement and then another Fifteen Thousand Dollars ($15,000) is due six months after the license commencement date. The Company also agrees to pay N.A.S.A. a minimum royalty of Fifteen Thousand Dollars ($15,000), at the end of each accounting period (“Accounting Period”). The Accounting Period shall begin at the end of the second Accounting period of the License Agreement and each Accounting period thereafter.

The License Agreement requires that the Company achieve a practical application of the Patent within eighteen (18) months from the commencement date of the License Agreement. In accordance with the appendix to the License Agreement; wherein it states that by August 2014, the Company shall have tested the product to meet federal, state and international regulations of its skin cream products, by October 2014, the Company shall have packaged and filled five products and by December 2014, the Company shall have Domestic and International distribution of five products. Once a practical application is achieved the term of the agreement shall be equal to the unexpired term of the last patent to be in effect of the patent(s) encompassed under the Patents.  The Company further agrees that any products using the Patents process shall be substantially manufactured in the United States.

The foregoing summary description of the License Agreement is not complete and is qualified in its entirety by reference to the full text of the License Agreement. The License Agreement also contains customary events of default. For further information regarding the terms and conditions of the License Agreement, this reference is made to such agreement, which the Company has filed as an exhibit 10.11 to the Quarterly Report on Form 10-Q that was filed the Securities and Exchange Commission on August 14, 2014, is incorporated  herein by this reference.

On August 28, 2014, the Board authorized the Company to exchange or repurchase 68,666,619 shares of common stock in privately negotiated transactions with three shareholders, including the current CEO of the Company. As a result of the exchange or repurchase the Company’s total shares issued and outstanding was reduced to Fifty Million One Hundred Eighteen Thousand Four Hundred Ninety Three 50,118,493 shares of common stock.

The repurchase was made pursuant to a privately negotiated stock repurchase agreement. The per share repurchase price for the shares repurchased was determined through arms-length negotiations with the private investors. The exchange of shares was consummated at the price that the shares were issued for originally.

9

The repurchase price was paid through cash on hand from the Company’s available surplus and through the issuance of unsecured promissory notes that accrue simple interest at 6% per annum. Other than this private transaction as described in this report, our board of directors has not authorized any stock repurchase program or plan, and we have no current plans to effect any open-market purchases of our common stock or other repurchases of our common stock.

A copy of the unsecured promissory note and press release announcing the share repurchase was attached to our Current Report on Form 8-K as Exhibits 10.1 and 99.1, respectively, that was filed with the Securities and Exchange Commission on August 28, 2014 and is incorporated herein by this reference.

On or about September 9, 2014, the Company established an Advisory Board to the Company. The first member appointed to the Advisory Board was Dr. Jacob G. Appelbaum who was also appointed the Chairman of the Advisory Board. Dr. Appelbaum is an internationally recognized physicist and multidisciplinary technologist. He currently serves as the CEO of Advanced Technology Department, Inc., and prior to that he served as a research professor at the Innovative Space Nuclear Power and Propulsion Instituted of the University of Florida.  Due to Dr. Appelbaum’s knowledge and experience we are very pleased to have him join the Company on our Advisory Board.

On or about September 11, 2014, the Company’s wholly-owned subsidiary Renuell, Int’l Inc., filed articles of amendment with the Florida Secretary of state and changed its name to Rejuvel, Int’l, Inc., in order to have a more marketable/memorable name, and better fit the brands image. The amendment went effective with the Florida Secretary of State on September 14, 2014. The subsidiary’s website has also changed and is now www.rejuvel.com.

On October 1, 2014, the Company signed an agreement with Strawberry Bullet, LLC, a New York based advertising agency that will assist the Company’s wholly-owned subsidiary Rejuvel, with market research, and branding services for its facial cream, as well as assisting with creating a marketing and advertising campaign for our subsidiary.  

On or about October 9, 2014, The Company completed a clinical study to test the efficacy of their products at Essex Testing Clinic in Verona, New Jersey. Team members on The Essex Testing Clinic staff included doctors, nurses, clinical study, recruitment professionals, quality assurance and trained evaluators and a large network of consulting physicians, all possessing considerable experience in clinical investigation. Team personnel evaluated facial imperfections of each subject and took scientific measurements to determine the firmness and elasticity of the skin to detect change.  

After 6 weeks of product use, 32 subjects responded with the following:

• 100% – Smoother and softer skin.

• 100% – Facial skin had an improved texture.

• 100% – Product regimen was gentle and non-irritating.

• 84.4% – Appearance of fine lines on face is less noticeable.

• 78.1% – Appearance of wrinkles on face is less noticeable.

• 81.3% – Improvement in the firmness/elasticity of skin.

• 75.0% – Reduction in the appearance of dark, under the eye circles.

• 84.4% – Skin appeared renewed and discolorations were reduced.

• 87.5% – Moisture content in skin had increased.

• 90.6% – Skin appears brighter and more radiant.

• 90.6% – Skin appears healthier.

• 93.8% – Skin appears refreshed.

• 87.5% – Overall appearance was improved.

Scientific Measurements results after 6 weeks of use are as follows:

• 78% of subjects Fine Lines/ Wrinkles were significantly reduced

• 88% of subjects Under Eye Discoloration significantly improved

• 78% of subjects Firmness/ Elasticity significantly improved

• 97% of subjects Skin Moisture significantly improved

10

The conclusion of this clinical study fulfills the requirements to be able to broadcast on the major home shopping channels.  Our next step is to voluntarily submit our testing claims to the Federal Drug Administration (FDA).

On or about October 13, 2014, the Company entered into an distribution agreement (“Distribution Agreement”) with Olgun Emirzade, who is a Director of Meditem Cyprus Limited (“Meditem”); thereby, naming Northern Cyprus as a non-exclusive territory for Meditem. The terms of the Distribution Agreement, expects that Meditem will sell a minimum of 200 units of skin cream a month for the first year, allows for Meditem to receive a finder’s fee for each 1.7oz bottle purchased by any newly referred distributor in the Republic of Cyprus. The Distribution Agreement is for a period of one year and then the two parties will evaluate the progress and the Distribution Agreement can be renewed for an additional five one year periods. The Distribution Agreement also calls for a quota to be established after the first year of the Distribution Agreement that the more territories and exclusivity to territories may be adjusted in further negotiations.

Customers

Rejuvel Int’l, Inc.

Our subsidiary Rejuvel Int’l, Inc., produces a skin cream under the names Renuéll,  Re’Juvel, and will have several potential target customers such as; retail customers, online purchasers from our website www.Rejuvel.com, skin care professionals, spas, doctors, and retail stores that sell cosmetic products. These potential customers will include the end user who can purchase the product online, management believes this customer will typically be middle aged persons, but also anyone who has a need or desire to have their skin look refreshed and younger. The other main potential customer that the Renuéll's skin cream will attempt to obtain is in the retail market, such as established pharmacies, retail and grocery store chains, where the product can be put on the shelves and start to gain brand recognition.

NueEarth, Inc.

The Company has three major types of potential customers for the e-beam water purification system: national and international corporations; municipalities, governments (domestic and foreign) and governmental agencies. With the e-beam unit mounted in a semi-trailer it is capable of being moved anywhere in North America with relative ease. Therefore, the Company can access most any site that has a road leading up to it.

Markets

Rejuvel Int’l, Inc

The target markets for the skin cream are located domestically in all 50 states, internationally in Europe as well as in the developing economies of Asia and Latin America. Management believes that through an online presence, retail presence and word of mouth that anywhere where people are looking for a non-surgical method to enhance their look that the skin cream has a potential market.

NueEarth, Inc.

Domestic Water Supply Crisis

Per capita usage of water in the United States is among the highest in the world. The supply of fresh water continues to tighten, especially in the Western half of the United States where we face a potential water crisis due to limited supply and increasing demand. Increasing usage of water in the industries such as oil and gas exploration and production, agriculture, and food processing continue to constrain supply of fresh water in the United States. For example, there are over 21 billion barrels of produced water created annually in the U.S. from fracking activity in the oil and gas industry, as each well requires millions of gallons of water for fracking over its life. In many areas, such as the Bakken or Marcellus shale plays, there is limited access to large scale, industry specific water treatment and recycling facilities which could drastically decrease the need for usage of fresh water in fracking.

Inadequate Regulatory Action

Poor quality of existing water management resources, combined with regulatory inaction, have failed to provide the leadership and guidance to mandate recycling and reuse of water resources in many industries. While

11

there has been a general lack of adequate water management regulation in many industries, management believes that recent regulatory action requiring more responsible water usage management in oil and gas fracking in states such as Pennsylvania is a trend that should drive similar action in other states, such as North Dakota. North Dakota’s oil and gas industry has no readily available, affordable source of water recycling and treatment. The current practice in North Dakota for wastewater created during fracking is to inject produced water back into the ground, a practice that has unknown effects on the environment and has come under heavy regulatory scrutiny in other States. Each horizontal new well requires millions of gallons of fresh water over its life, contributing heavily to the supply crisis. Any regulatory actions affecting the legality of fresh water usage in fracking or injection of produced water back into the ground could negatively affect the oil and gas industry in North Dakota and increase industry demand for water treatment and recycling services.

In addition to the oil and gas industry, the domestic agricultural industry is generally lacking in sufficient water management regulations. Until a concerted private/public effort is expended, the contaminated acreage will continue to expand. Management believes the excess use of water and lack of regulation in the agricultural industry will result in regulatory changes which drastically increase the domestic demand for various water treatment and recycling services.

Growing Need for Affordable Regulatory Compliance

In the United States the Environmental Protection Agency (“EPA”) 2009 National Public Water Systems Compliance Report, states that there were over 150,000 public rural water districts in the United States serving over 300 million users. The majority of these are considered very small, small and medium-sized public water systems, which support populations of fewer than 10,000 people. Small systems comprise the vast majority of all systems. Noncompliance occurs more frequently at smaller systems often because they may have fewer resources to operate and maintain compliance. This problem is expected to worsen as more stringent EPA rules are implemented for small public water systems. Approximately 28 percent of all systems in the U.S. had at least one significant violation reported in 2009. This rate is comparable to those reported in previous years. The data submitted by primacy agencies indicate that 7 percent of all public water systems in the U.S., serving approximately 17,693,000 users, had violations of health-based standards in 2009.  In 2009, about 18 percent of all public water systems had significant monitoring and reporting violations. Substantial expenditures will be needed in the coming years for repair, rehabilitation, operation, and maintenance of the water and wastewater treatment infrastructure. Management believes that water districts using conventional treatment methods will be unable to comply with the EPA’s Safe Drinking Water Act (“SDWA”) without massive installations of on-site chemical filter aids and disinfection equipment.

Consumer Safety

Drinking water, regardless of its source, may contain impurities that can affect the health of consumers. Although municipal agencies and water utilities in the United States are required to provide drinking water that complies with the 1996 amendments to the SDWA, the water supplied to homes and businesses from municipalities and utilities may contain high levels of bacteria, toxins, parasites and human and animal-health pharmaceuticals, as well as high levels of chlorine used to eliminate contaminants. In the industrialized world, water quality is often compromised by pollution, aging municipal water systems, and contaminated wells and surface water. In addition, the specter of terrorism directed at intentional contamination of water supplies has heightened awareness of the importance of reliable and secure water purification. The importance of effective water treatment is also critical from an economic standpoint, as health concerns and impure water can impair consumer confidence in food products. Discharge of impaired waters into the environment can further degrade the earth’s water and violate environmental laws, with the possibility of significant fines and penalties from regulatory agencies.

Sales and Marketing

Management plans to focus the marketing strategy on educating prospective customers and the trade industry about the Company, so that the products and services are successfully brought to market. The Company plans to sell and market the products and services through attendance at major trade and industry exhibitions, one-on-one sales meetings with individual customers and using social media and marketing and advertising campaigns.

The Company continues to search for retailers and distributors both nationally and abroad for all of its products.

12

Manufacturing and Raw Materials

Rejuvel Int’l, Inc.

The Company produces, supply’s the product components and formulates our skin creams and we rely on third-parties to package the finished goods. Third parties also provide order fulfillment, warehousing and distribution services. The Company plans to produce its product in larger production batches thereby increasing production efficiency, which will reduce costs.

We manufacture the products and provide the raw materials for the skin cream that our Company distributes. Third-parties are responsible for the receipt and storage of raw material, production and packaging and labeling of finished goods. The Company believes at the present time it will be able to obtain the quantity of products and supplies it will need to meet orders.

The Company produces all of the raw materials that we require to formulate our skin cream. The Company also relies on third party carriers for product shipments, including shipments to and from distribution facilities. It is therefore subject to the risks, including employee strikes and inclement weather, associated with the carriers’ ability to provide delivery services to meet the Company’s fulfillment and shipping needs. Failure to deliver products to customers in a timely and accurate matter would harm the Company’s reputation, business and results of operations.

Patents, Trademarks and Licenses

The trademarks currently owned by the Company, and for which it intends to seek federal transaction registration are the marks NueEarth™, Re’Juvel™, Bio-Science™, NueCell™, NueStem Cell Matrix™ and NueStem Cell Lattice™. The Company may federally register other trademarks in the future as the need arises. It intends to patent the processes and designs as the need arises; however, the Company currently does not have any federally registered patents.

Competition

Rejuvel Int’l, Inc.

The skin care and personal care industries are highly competitive. Many of the Company’s competitors are large, well-known companies that have considerably greater financial, sales, marketing, research and development and technical resources in the company. Additionally, these competitors have formulary capabilities that may allow them to formulate new and improved products that may compete with product lines that the Company develops and markets. In addition, competitors may elect to devote substantial resources to marketing their products to similar outlets and may choose to develop advertising, educational and information programs like this formulated by the Company to support their marketing efforts. The Company’s business, financial condition and results of operations could be materially and adversely affected by any one or more of such developments.

The Company’s product, in general, competes against similar products distributed by national skin care and personal care companies. Management believes the Company’s competitive position is based on the foundation of developing niche products with active ingredients that may not be found in generic products. The Company’s competitive strategy is based on management’s attempt to continually focus on the application of new technologies and efficiencies rather than fashions or trends.

NueEarth, Inc.

The technology industry is highly competitive and varied. Many of the existing and potential competitors have financial, personnel, marketing, customer bases and other financial resources significantly greater than the Companies. These competitors have the flexibility to introduce new products and services and pricing options that may be more attractive than the Companies.  The Company’s water purification process competes with several companies, including but not limited to, Clean Harbors Environmental Services, Vac Vision, and the Zenon Group. The Company will attempt to overcome the competitive advantages of its competitors by pursuing a strategy of developing technologies in niche markets which seek to provide the Company with brand name recognition.

13

Government Regulation

Rejuvel Int’l, Inc.

Unless the FDA extends its regulatory authority to cosmetic products, regulation by governmental authorities in the United States and other countries is not expected to be a significant consideration in the sale of the products by Rejuvel Int’l, Inc. and its ongoing activities. Under current regulations, the market introduction of the majority of non-medicated cosmetic products does not require prior formal registration or approval by the FDA, although this could change in the future. The cosmetic industry has established self-regulating procedures and most companies perform their own toxicity and consumer tests. Voluntary filings related to manufacturing facilities are made with the FDA. The Cosmetics Division of the FDA, however, does monitor closely problems of safety, adulteration and labeling. In addition, if the FDA should determine that claims made by the Company for the products involve the cure, mitigation or treatment of disease, the FDA could take regulatory action against the products and us. In addition, the United States Federal Trade Commission (“FTC”) monitors product claims made in television and radio commercials and print advertising to ensure that any claim can be substantiated. If the FTC believes that any advertising claim made by the Company with regard to the effect or benefit of the products is not substantiated by adequate data or research and the Company cannot support such claim, the FTC could also take regulatory action against the Company’s products and us.

NueEarth, Inc.

The business activities relating to NueEarth, Inc. are subject to environmental regulation under the same federal, state and local laws and regulations which apply to the Company’s customers, including the Clean Water Act of 1972, as amended, and the Resource Conservation and Recovery Act of 1976, as amended. Management believes that the Company conducts its business in an environmentally responsible manner and is in material compliance with applicable laws and regulations. It is possible that future developments, such as increasingly strict requirements of environmental laws and enforcement policies thereunder, could affect the manner in which the Company operates projects and conducts business, including the handling, processing or disposal of the wastes, by-products and residues generated thereby.

Employees

Charles J. Scimeca is our sole officer and director who serves on a full-time basis. None of our employees is represented by a labor union for purposes of collective bargaining. We consider our relations with our employees to be good.

WHERE YOU CAN GET ADDITIONAL INFORMATION

We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy our reports or other filings made with the SEC at the SEC’s Public Reference Room, located at 100 F Street, N.E., Washington, DC 20549. You can obtain information on the operations of the Public Reference Room by calling the SEC at 1-800-SEC-0330. You can also access these reports and other filings electronically on the SEC’s web site, www.sec.gov.

ITEM 1A. RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item. We reserve the right not to provide risk factors in our future filings. Our primary risk factors and other considerations include:

Because the Company auditors have issued a going concern opinion, there is a substantial uncertainty that it will continue operations in which case one could lose one’s investment.

The auditors have issued a going concern opinion because of the Company’s recurring losses, negative working capital, stockholder’s deficit and the absence of revenue-generating operations.  This means that there is substantial doubt that it can continue as an ongoing business for the next twelve months. As such it may have to cease operations and you could lose your entire investment.

14

Mr. Scimeca and Mr. Stickler the Company’s two officers who also serve as the Company’s directors, currently devote approximately 30-40 hours per week to Company matters.  Neither of the two Company’s officers have much public company experience, and they are also involved in other business activities.  The Company’s needs could exceed the amount of time or level of experience they may have.  This could result in their inability to properly manage Company affairs, resulting in it remaining a start-up company with no revenues or profits.

Currently, Mr. Scimeca and Mr. Stickler serve as the only officers and directors of the Company.  The Company business plan does not provide for the hiring of any additional employees other than outlined in its Plan of Operations until sales will support the expense. Until that time the responsibility of developing the Company’s business and fulfilling the reporting requirements of a public company all fall upon the Company’s two officers who also serve as the Company’s directors.  While their business experience includes some management and marketing, though Charles J. Scimeca has had experience as a consultant to private companies going public, they do not have experience in a public company setting, including serving as a principal accounting officer or principal financial officer to a public company.  There is no formulated plan to resolve any possible conflict of interest with their other business activities.  In the event they are unable to fulfill any aspect of their duties to the Company, the Company may experience a shortfall or complete lack of sales resulting in little or no profits and eventual closure of its business.

Since we are a development stage company, that has generated minimal revenues and lacks an operating history, an investment in the shares offered herein is highly risky and could result in a complete loss of your investment if the Company is unsuccessful in its business plans.

This Company was incorporated in October 2009; it has just commenced its business operations; and it has generated minimal revenue.  There is minimal operating history upon which an evaluation of its future prospects can be made.  Based upon current plans, the Company expects to incur operating losses in future periods as it incurs significant expenses associated with the initial startup of its business.  Further, there is no guarantee that it will be successful in realizing revenues or in achieving or sustaining positive cash flow at any time in the future.  Any such failure could result in the possible closure of its business or force the company to seek additional capital through loans or additional sales of its equity securities to continue business operations, which would dilute the value of any shares you purchase.

The Company cannot predict when or if it will produce revenues which could result in a total loss of your investment if it is unsuccessful in its business plans.

The Company has generated only minimal revenues from operations.  In order for it to continue with its plans and keep the business operating, it must raise capital to do so.  There can be no assurance that it will generate more than minimal revenues or that those revenues will be sufficient to maintain its business.  As a result, one could lose all of one’s investment if one decides to purchase shares in this Company and it is not successful in its proposed business plans.

Commencement and development of operations will depend on the acceptance of its proposed business.  If the Company products are not deemed desirable and suitable for purchase and it cannot establish a customer base, it may not be able to generate any revenues, which would result in a failure of the business and a loss of any investment one makes in the shares.

The acceptance of the Company’s enhanced skin care products and the e-beam water purifier is critically important to its success. The Company cannot be certain that the products that it will be offering will be appealing and as a result there may not be any demand for these products and its sales could be limited and it may never realize any revenues. In addition, there are no assurances that if it alters or changes the products it offers in the future that the demand for these new products will develop and this could adversely affect the Company’s business and any possible revenues.

If demand for the products and services that the Company plans to offer slows, then its business would be materially affected.

Demand for products which it intends to sell depends on many factors, including:

• the economy, and in periods of rapidly declining economic conditions, customers may defer luxury purchases or may choose alternate products.

15

• the competitive environment in the skin care and water purification sectors may force it to reduce prices below its desired pricing level or increase promotional spending;

• our ability to anticipate changes in consumer preferences and to meet customers’ needs for skin care products in a timely cost-effective manner;

• our ability to maintain efficient, timely and cost-effective production and delivery of the products and services; and,

• our ability to identify and respond successfully to emerging trends in the skin care, hair care, personal care, and water purification industries.

For the long term, demand for the products and services that it plans to offer may be affected by:

• the ability to establish, maintain and eventually grow market share in a competitive environment;

• our ability to deliver of our products and services globally, geopolitical changes, changes in government regulations, currency fluctuations, natural disasters, pandemics and other factors beyond the Company’s control may increase the cost of items it purchases, create communication issues or render product delivery difficult which could have a material adverse effect on its sales and profitability; and,

• restrictions on access to North American markets and supplies.

All of these factors could result in immediate and longer term declines in the demand for the products and services that it plans to offer, which could adversely affect its sales, cash flows and overall financial condition.

The loss of the services of our two current officers and directors could severely impact the Company business operations and future development, which could result in a loss of revenues and one’s ability to ever sell any shares.

The Company’s performance is substantially dependent upon the professional expertise of its two current officers and directors.  The Company is dependent on their abilities to develop its business. If they were unable to perform their duties, this could have an adverse effect on Company business operations, financial condition and operating results if it is unable to replace them with other individuals qualified to develop and market its business. The loss of their services could result in a loss of revenues, which could result in a reduction of the value of any shares you purchase in this Company.

The Skin Care and Water Purification industries are highly competitive.  

The Company, through its two wholly-owned subsidiaries, expects to compete against a number of large well-established skin care and water purification companies with greater name recognition, a more comprehensive offering of products, and with substantially larger resources than the Company’s; including financial and marketing. In addition to these well-established competitors there are some smaller companies that have developed and are marketing similar products. There can be no assurance that it can compete successfully in the North American or Global markets.  If it cannot successfully compete in these highly competitive markets, it may never be able to generate revenues or become profitable.

The Company may not be able to successfully implement its business strategy, which could adversely affect its business, financial condition, results of operations and cash flows.

Successful implementation of its business strategy depends on factors specific to skin care products and the water purification market and numerous other factors that may be beyond its control.  Adverse changes in the following factors could undermine the business strategy and have a material adverse effect on its business, its financial condition, and results of operations and cash flow.

16

We may be unable to protect the Company’s intellectual property rights and may be subject to intellectual property litigation and infringement claims by third-parties.

We intend to protect the Company’s unpatented trade secrets and know-how through confidentiality or license agreements with third-parties, employees and consultants, and by controlling access to and distribution of our proprietary information. However, this method may not afford complete protection particularly in foreign countries where the laws may not protect the proprietary rights as fully as in the United States and unauthorized parties may copy or otherwise obtain and use the Company’s products, processes or technology and there can be no assurance that others will not independently develop similar know-how and trade secrets. If third-parties take actions that affect the Company’s rights or the value of its intellectual property, similar proprietary rights or reputation or it is unable to protect its intellectual property from infringement or misappropriation, other companies may be able to use its proprietary know-how to offer competitive products at lower prices and the Company may not be able to effectively compete against these companies.

The Company also faces the risk of claims that it has infringed third-parties’ intellectual property rights. Any claims of intellectual property infringement, even those without merit, could expose the Company to the following risks, among others, it may be required to:

• Defend against infringement claims which are expensive and time consuming;

• Cease making, licensing or using products that incorporate the challenged intellectual property;

• Re-design, re-engineer or re-brand the products or packaging; or,

• Enter into royalty or licensing agreements in order to obtain the right to use a third-party’s intellectual property.

Like other retailers, distributors and manufacturers of skin care and personal care products, the Company faces an inherent risk of exposure to product liability claims in the event that the use of the products that it sells results in injury.

While management believes the Company is currently materially compliant with regulations covering its products, it may be subjected to various product liability claims, including claims that the products it sells contain contaminants, are improperly labeled or include inadequate instructions as to use or inadequate warnings concerning side effects and interactions with other substances. In addition, it may be forced to defend lawsuits. While to date the Company has never been subject to any product liability claim, it cannot predict whether product liability claims will be brought against it in the future or the effect of any resulting adverse publicity on the business. Moreover, the Company may not have adequate resources in the event of a successful claim against it. If its insurance protection is inadequate and third-party vendors do not indemnify the Company, the successful assertion of product liability claims against it could result in potentially significant monetary damages. In addition, interactions of the products with other similar products, prescription medicines and over-the-counter drugs have not been fully explored.

The Company may also be exposed to claims relating to product advertising or product quality. People may purchase its products expecting certain physical results, unique to skin care and personal care products. If they do not perceive expected results to occur, certain individuals or groups of individuals may seek monetary retribution.

If our products become contaminated, our business could be seriously harmed.

We have adopted various quality, environmental, health and safety standards. However, our products may still not meet these standards or could otherwise become contaminated. A failure to meet these standards or contamination could occur in our operations or those of our bottlers, manufacturers, distributors or suppliers. Such a failure or contamination could result in expensive production interruptions, recalls and liability claims. Moreover, negative publicity could be generated even from false, unfounded or nominal liability claims or limited recalls. Any of these failures or occurrences could negatively affect our business and financial performance.

The Company’s business may be adversely affected by unfavorable publicity within the skin care or water purification markets.

Management believes that the skin care and water purification markets are significantly affected by national media attention. As with any retail provider, future scientific research or publicity may not be favorable to the industry or to any particular product, and may not be consistent with earlier favorable research or publicity. Because of the Company’s dependence on consumers’ perceptions, adverse publicity associated with illness or other adverse effects resulting from the use of its products or any similar products distributed by other companies and

17

future reports of research that are perceived as less favorable or that question earlier research, could have a material adverse effect on the Company’s business, financial condition and results of operations. The Company is highly dependent upon consumers’ perceptions of the safety and quality of the products as well as similar products distributed by other companies. Thus, the mere publication of reports asserting that skin care or personal care products may be harmful or questioning their efficacy could have a material adverse effect on the Company’s business, financial condition and results of operations, regardless of whether such reports are scientifically supported or whether the claimed harmful effects would be present at the dosages recommended for such products.

As the Company intends to be conducting international business transactions, it will be exposed to local business risks in different countries, which could have a material adverse effect on its financial condition or results of operations.

The Company intends to promote and sell its products internationally by virtue of the global access to its skin care products line and it expects to have customers located in several countries. The Company’s international operations will be subject to risks inherent in doing business in foreign countries, including, but not necessarily limited to:

• new and different legal and regulatory requirements in local jurisdictions;

• potentially adverse tax consequences, including imposition or increase of taxes on transactions or withholding and other taxes on remittances and other payments by subsidiaries;

• risk of nationalization of private enterprises by foreign governments;

• legal restrictions on doing business in or with certain nations, certain parties and/or certain products; and,

• local economic, political and social conditions, including the possibility of hyperinflationary conditions and political instability.

The Company may not be successful in developing and implementing policies and strategies to address the foregoing factors in a timely and effective manner in the locations where it will do business. Consequently, the occurrence of one or more of the foregoing factors could have a material adverse effect on its base operations and upon its financial condition and results of operations.

Since our products will be available over the Internet in foreign countries and the Company will have customers residing in foreign countries, foreign jurisdictions may require it to qualify to do business in their country. It will be required to comply with certain laws and regulations of each country in which it conducts business, including laws and regulations currently in place or which may be enacted related to Internet services available to the residents of each country from online sites located elsewhere.

The Company operations in developing markets could expose it to political, economic and regulatory risks that are greater than those it may face in established markets. Further, its international operations may require it to comply with additional United States and international regulations.

For example, it may be required to comply with the Foreign Corrupt Practices Act, or "FCPA," which prohibits companies or their agents and employees from providing anything of value to a foreign official or agent thereof for the purposes of influencing any act or decision of these individuals in their official capacity to help obtain or retain business, direct business to any person or corporate entity or obtain any unfair advantage. The Company may operate in some nations that have experienced significant levels of governmental corruption. Its employees, agents and contractors, including companies to which it outsources business operations, may take actions in violation of its policies and legal requirements. Such violations, even if prohibited by its policies and procedures, could have an adverse effect on its business and reputation. Any failure by the Company to ensure that its employees and agents comply with the FCPA and applicable laws and regulations in foreign jurisdictions could result in substantial civil and criminal penalties or restrictions on its ability to conduct business in certain foreign jurisdictions, and its results of operations and financial condition could be materially and adversely affected.

In addition, the Company’s ability to attract and retain customers may be adversely affected if the reputations of the other enhanced skin care products or water purification systems rely on faulty science. The perception of untrustworthiness within the skin care industry or of water purification could materially adversely affect its ability to attract and retain customers.

18

If the Company fails to promote and maintain its brand in the market, the businesses, operating results, financial condition, and ability to attract customers will be materially adversely affected.

The Company’s success depends on its ability to create and maintain brand awareness of its product and service offerings. This may require a significant amount of capital to allow it to market the products and establish brand recognition and customer loyalty. Many of its competitors in this market are larger than the Company and have substantially greater financial resources. Additionally, many of the companies offering similar products have already established their brand identity within the marketplace. The Company can offer no assurances that it will be successful in establishing awareness of its brand allowing it to compete in this market. The importance of brand recognition will continue to increase because low barriers of entry to the industries in which the Company operates may result in an increased number of direct competitors. To promote its brands, the Company may be required to continue to increase its financial commitment to creating and maintaining brand awareness. It may not generate a corresponding increase in revenue to justify these costs.

The Company’s Renuéll skin cream products may require FDA approved testing to establish benefit claims and their efficacy.

While the majority of the active ingredients in the Rejuvel skin cream products have undergone independent third-party testing to establish benefit claims and efficacy, certain ingredients contained in the products and its future products may require FDA approved testing to establish the benefit claims or their safety and efficacy. Such testing can require a significant amount of resources and there is no assurance that such testing will be favorable to the claims the Company makes for the products, or that the cumulative authority established by such testing will be sufficient to support the claims. Moreover, both the findings and methodology of all FDA approved testing are subject to challenge by scientific bodies. If the findings of FDA approved testing are challenged or found to be insufficient to support the claims, additional testing may be required, or products may require re-formation, in order for the Company to continue to market current products or before future products can be marketed. Furthermore, there are limited studies, if any, on the product ingredients combined in the product formulations. Accordingly, there can be no assurance that the products, even when used as directed, will have the effects intended. In the event the Company is unable to substantiate benefit claims or efficacy, or in the event that historical testing is refuted, market acceptance for the products may decrease or not develop, which would have a detrimental effect on the Company’s business.

As an “emerging growth company” under the jumpstart our business startups act (the “JOBS Act”), the Company is permitted to rely on exemptions from certain disclosure requirements.

TAIC qualifies as an “emerging growth company” under the JOBS Act. As a result, it is permitted to, and intends to, rely on exemptions from certain disclosure requirements. For so long as the Company is an emerging growth company, it will not be required to:

• have an auditor report on its internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act;  

• comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (i.e., an auditor discussion and analysis);  

• submit certain executive compensation matters to shareholder advisory votes, such as “say-on-pay” and “say-on-frequency;” and  

• disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO’s compensation to median employee compensation.

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company will remain an emerging growth company for up to five full fiscal years, although if the market value of its common stock that is held by non-affiliates exceeds $700 million as of any June 30 before that time, it would cease to be an emerging

19

growth company as of the following December 31, or if its annual revenues exceed $1 billion, it would cease to be an emerging growth company the following fiscal year, or if it issues more than $1 billion in non-convertible debt in a three-year period, the Company would cease to be an emerging growth company immediately.

The Company will elect to take advantage of the extended transition period for complying with new or revised accounting standards under section 102(b)(1).

This election allows the Company to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election the financial statements may not be comparable to companies that comply with public company effective dates.

ITEM 1B.  UNRESOLVED STAFF COMMENTS

None.

ITEM 2.  PROPERTIES

Our corporate headquarters are located at Chase Bank Building 150 SE 2nd Ave, Suite 403 Miami, Florida 33131. On September 10, 2014, the Company signed a lease agreement for office used. Lease term is twenty-six months from October 1, 2014. Rental is $42,333 for twelve months.

Year	Commitment Payment
2015	$42,333
2016	$38,806

As of the date of this filing, the Company has not sought to move our office. Additional space may be required as the Company expands its operations. Management does not foresee any significant difficulties in obtaining any required additional space. The Company currently does not own any real property.

ITEM 3.  LEGAL PROCEEDINGS

We know of no material, existing or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which our director, officer or any affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

ITEM 4.  MINE SAFETY DISCLOSURES

Not Applicable.

20

PART II

ITEM 5.  MARKET FOR THE COMPANY’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Common Stock

Our common stock is currently quoted on the OTC Markets. Our common stock has been quoted on the OTC Markets since March 25, 2014, trading under the symbol “TCHA.”  On March 31, 2014 our symbol was changed to “NUUU” to reflect our Company’s skin care line. Because we are quoted on the OTC Markets, our securities may be less liquid, receive less coverage by security analysts and news media, and generate lower prices than might otherwise be obtained if they were listed on a national securities exchange.

The following table sets forth the high and low bid prices for our Common Stock per quarter as reported by the OTCBB since we began trading February 12, 2014 based on our fiscal year end December 31. These prices represent quotations between dealers without adjustment for retail mark-up, markdown or commission and may not represent actual transactions.  

2014FISCAL YEAR	High	Low
First Quarter	$4.50	$1.50
Second Quarter	$2.75	$1.20
Third Quarter	$1.75	$1.15
Fourth Quarter	$1.44	$0.10

Record Holders

As of April 15, 2015, there were 50,473,093 shares of the registrant’s $0.001 par value common stock issued and outstanding and were owned by approximately 85 holders of record, based on information provided by our transfer agent.

Recent Sales of Unregistered Securities

In February and April 2014, the Noteholder elected to convert $274,000 (including accrued interest of $30,816) into 607,149 shares of the Company’s Common Stock at $0.50 per share.  The Company issued 607,149 warrants to purchase 607,149 shares of common stock exercisable at $1.00 per share. The warrants were all expired by October 2014.

In March 2014, the Company issued 601,000 shares of its common stock at $0.50 through a private placement for total cash consideration of $300,500. Also, the Company issued 601,000 warrants to purchase 601,000 shares of common stock exercisable at $1.00 per share. 34,000 warrants were exercised in September 2014 and 567,000 warrants were expired in September 2014.

On April 3, 2014, the Company entered stock subscription agreement of 5,000 shares at $1.00 per share with 5,000 warrants to purchase 5,000 shares of common stock with an exercise price of $2.00 per share.  These warrants expired 180 days after stock issuance date in September 2014.

On April 16, 2014, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 20,000 warrants to purchase 20,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expired 180 days after stock issuance date in October 2014

On July 7, and July 31, 2014, the Company entered stock subscription agreements of 50,000 shares and 20,000 shares at $1.00 per share with 50,000 and 20,000 warrants to purchase 50,000 and 20,000 shares of common stock with an exercise price of $2.00 per share.  These warrants expire 360 days after stock issuance date.

On August 22, 2014, the Company entered stock subscription agreement of 99,963 shares at $1.00 per share with 99,963 warrants to purchase 99,963 shares of common stock with an exercise price of $2.00 per share.  These warrants expire 1 year after the stock issuance date.

21

On September 9, 2014, a Warrant holder exercised 34,000 warrants to purchase 34,000 restricted common shares at a price of $1.00 per share.

On October 1, 2014, the Company entered a consulting agreement whereby the Company issued 15,000 shares for consulting services, for a period from February 9, 2015 until March 9, 2015.

On December 28, 2014, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 20,000 warrants to purchase 20,000 shares of common stock with an exercise price of $2.00 per share.  These warrants expire 360 days after stock issuance date.

These securities were issued pursuant to Section 4(2) of the Securities Act and/or Rule 506 promulgated thereunder. The holders represented their intention to acquire the securities for investment only and not with a view towards distribution. The investors were given adequate information about us to make an informed investment decision. We did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates with the appropriate restrictive legend affixed to the restricted stock.

Other than as previously disclosed, none.

Subsequent Issuances:

On January 27, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of 1.00 per share.  These warrants expire 360 days after stock issuance date.

On February 2, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 360 days after stock issuance date.

On February 2, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 360 days after stock issuance date.

On February 3, 2015, the Company entered stock subscription agreement for 21,600 shares at $0.50 per share.

On February 18, 2015, the Company entered stock subscription agreement of 50,000 shares at $0.50 per share with 50,000 warrants to purchase 50,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 360 days after stock issuance date.

On February 18, 2015, the Company entered a consulting agreement whereby the Company issued 15,000 shares for consulting services, on a month to month basis.

On February 19, 2015, the Company entered a consulting agreement whereby the Company issued 25,000 shares for consulting services, on a month to month basis.

On February 21, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 360 days after stock issuance date.

On February 21, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 360 days after stock issuance date.

On February 21, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 360 days after stock issuance date.

22

On February 23, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 360 days after stock issuance date.

On or about February 26, 2015, the Company entered into a distribution agreement (“Distribution Agreement”) with Yontem Cosmetics Dis Tic. Ltd. Sti (“Yontem”) a Turkish company; thereby, naming Turkey (the “Territory”) as an exclusive territory for Yontem.  The terms of the Distribution Agreement, expects that Yontem will sell a minimum of 1,000 1.7oz units per month during the 1^st year, 2,000 1.7oz units per month during the second year of operation and 3,000 units per month in the third year upon the establishment of the company by Yontem. The Distribution Agreement is for an initial period of three years and then the two parties will evaluate the progress of the Distribution Agreement. The Distribution Agreement can then be renewed for an additional five-five year periods. The Distribution Agreement also states that in order to maintain exclusivity on the Territory the quota numbers must be met, and that if they are not met then Yontem will lose exclusivity to the Territory.

On March 6, 2015, the Company entered a service agreement whereby the Company issued 15,000 shares for marketing solution and strategy services, on a month to month basis.

On March 10, 2015, the Company entered stock subscription agreement of 50,000 shares at $0.50 per share with 50,000 warrants to purchase 50,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 360 days after stock issuance date.

On March 10, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 360 days after stock issuance date.

On March 14, 2015, the Company entered an independent contractor agreement whereby the Company issued 100,000 shares for medical services, for a period of one year.

On March 14, 2015, the Company entered an independent contractor agreement whereby the Company issued 10,000 shares for medical services, for a period of one year.

These securities were issued pursuant to Section 4(2) of the Securities Act and/or Rule 506 promulgated thereunder. The holders represented their intention to acquire the securities for investment only and not with a view towards distribution. The investors were given adequate information about us to make an informed investment decision. We did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates with the appropriate restrictive legend affixed to the restricted stock.

Re-Purchase of Equity Securities

None.

Dividends

We have not paid any cash dividends on our common stock since inception and presently anticipate that all earnings, if any, will be retained for development of our business and that no dividends on our common stock will be declared in the foreseeable future. Any future dividends will be subject to the discretion of our Board of Directors and will depend upon, among other things, future earnings, operating and financial condition, capital requirements, general business conditions and other pertinent facts. Therefore, there can be no assurance that any dividends on our common stock will be paid in the future.

Securities Authorized for Issuance Under Equity Compensation Plans

None.

ITEM 6. SELECTED FINANCIAL DATA

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

23

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements are not historical facts but rather are based on current expectations, estimates and projections. We may use words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “foresee,” “estimate” and variations of these words and similar expressions to identify forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted. You should read this report completely and with the understanding that actual future results may be materially different from what we expect. The forward looking statements included in this report are made as of the date of this report and should be evaluated with consideration of any changes occurring after the date of this Report. We will not update forward-looking statements even though our situation may change in the future and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Working Capital

	December 31, 2014 $	December 31, 2013 $
Current Assets	53,053	84,662
Current Liabilities	938,162	1,207,335
Working Capital (Deficit)	(885,109)	(1,122,673)

Cash Flows

	December 31, 2014 $
Cash Flows from (used in) Operating Activities	(493,785)
Cash Flows from (used in) Investing Activities	(33,335)
Cash Flows from (used in) Financing Activities	561,730
Net Increase (decrease) in Cash During Period	34,610

Results for the Year Ended December 31, 2014 Compared to the Year Ended December 31, 2013

Revenues:

The Company’s revenues were $94,096 for the year ended December 31, 2014 compared to $51,559 in 2013.  This represents an increase of $42,537 or 83%.  The increase is directly attributable to the Company sales of its Rejuvel cream.

Cost of Revenues:

The Company’s cost of revenue was $83,304 for the year ended December 31, 2014 compared to $26,805 in 2013.  This represents an increase of $56,499 or 211%.  The increase in cost of revenues is directly attributable to the increase in sales during 2013.

Gross Profit:

For the twelve months ended December 31, 2014, our total gross profit decreased by $13,962 or 177% to $10,792 from $24,754 in 2013. The decrease is attributable to product costs and writing off obsolete inventory.

General and Administrative Expenses:

General and administrative expenses consisted primarily of consulting fees, rent, travel, meals and entertainment, and preparing reports and SEC filings relating to being a public company.  For the year ended December 31, 2014, general and administrative expenses increased to $697,997 compared to $554,460 for the year

24

ended December 31, 2013, representing an increase of $143,537 or 26%.  The increase is primarily attributable to increases in advertising and marketing costs, consulting fees and officer compensation.

Other Income (Expense):

Other income (expense) consisted of gain on derivative valuation, derivative expense, and interest expense.  The gain on derivative valuation is directly attributable to the change in fair value of the derivative liability from date of issuance during 2013 through December 31, 2014. Derivative expense is primarily attributable the initial proceeds over the valuation of derivative instruments at issuance. Interest expense is primarily attributable to the accretion of the convertible debentures over their respective terms and accrued interest during the year. As of December 31, 2014, the Company had $700,279 gain on derivative valuation, $(267,253) of derivative expense, and $(98,686) interest expense.

Net Loss:

Our net loss for the year ended December 31, 2014 was $352,865 compared to a net loss of $715,546 for the year ended December 31, 2013, a decrease of $362,681 or 51%.  The net loss is influenced by the matters discussed in the other sections of this MD&A.

Impact of Inflation

We believe that the rate of inflation has had a negligible effect on our operations.

Liquidity and Capital Resources

The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan. Since its inception, the Company has been funded by related parties through capital investment and borrowing funds.

As of December 31, 2014, total current assets were $53,053, which consisted primarily of cash, inventory and deposits.

As of December 31, 2014, total current liabilities were $938,162, which consisted primarily of accounts payable and accrued expenses, a loan from a related party, related party advances and derivative liability. We had net working capital deficit of $(885,109) as of December 31, 2014.

Intangible Assets

The Company’s intangible assets were $15,859 net of amortization as of December 31, 2014.

Material Commitments

The Company’s material commitments were $0 as of December 31, 2014.

Going Concern

We have not attained profitable operations and are dependent upon obtaining financing to pursue any extensive acquisitions and activities. For these reasons, our auditors stated in their report on our audited financial statements that they have substantial doubt that we will be able to continue as a going concern without further financing.

Future Financings

We will continue to rely on equity sales of our common shares in order to continue to fund our business operations. Issuances of additional shares will result in dilution to existing stockholders. There is no assurance that we will achieve any additional sales of the equity securities or arrange for debt or other financing to fund planned acquisitions and exploration activities.

25

Off-Balance Sheet Arrangements

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.

Critical Accounting Policies

Our financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.

We regularly evaluate the accounting policies and estimates that we use to prepare our financial statements. A complete summary of these policies is included in the notes to our financial statements. In general, management's estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.

Recently Issued Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Contractual Obligations

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

26

ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

TECHNOLOGY APPLICATIONS INTERNATIONAL CORPORATION AND SUBSIDIARIES
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
AND
CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2014
FINANCIAL STATEMENT TABLE OF CONTENTS
December 31, 2014
Independent Registered Public Accounting Firm
Sadler Gibb & Associates, LLC	F-2
Consolidated Financial Statements
Balance Sheets	F-3
Statements of Operations	F-4
Statements of Shareholder’s Equity	F-5
Statements of Cash Flows	F-6
Notes to Consolidated Financial Statements	F-7

F- 1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors

Technology Applications International Corp

We have audited the accompanying consolidated balance sheets of Technology Applications International Corp. (the Company) as of December 31, 2014 and 2013 and the related consolidated statements of operations, stockholders’ deficit and cash flows for the years then ended.  These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.    

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Technology Applications International Corp. as of December 31, 2014 and 2013, and the results of their operations and cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company had accumulated losses of $2,157,774 and negative cash flows from operations as of December 31, 2014, which raises substantial doubt about its ability to continue as a going concern. Management’s plans concerning these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ Sadler, Gibb & Associates, LLC

Salt Lake City, UT

April 15, 2015

F- 2

TECHNOLOGY APPLICATIONS INTERNATIONAL CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
		December 31,		December 31,
ASSETS		2014		2013
Current assets
Cash and cash equivalents	$	39,501	$	4,891
Inventories		4,831		70,862
Deposits		7,000		7,000
Other current assets		1,722		1,909
Total current assets		53,053		84,662
Intangible assets, net		15,859		1,940
Machinery and equipment, net		32,092		19,371
Other Assets
Security deposits		3,725		-
Total assets	$	104,728	$	105,973
LIABILITIES AND SHAREHOLDERS' DEFICIT
Liabilities
Accounts payable and accrued expenses	$	458,783	$	344,415
Advances from affiliate		270,747		237,480
Loan from affiliate		157,068		77,401
Convertible debentures (net of debt discount of $zero and $75,902, respectively)		-		198,099
Deferred rent		2,713		-
Derivative liability		48,851		349,940
Total current liabilities		938,162		1,207,335
Total liabilities		938,162		1,207,335
Shareholders' deficit
Preferred stock, par value, $0.001 per share, 50,000,000 shares
authorized, none issued or outstanding		-		-
Common stock, par value $0.001 par value, 300,000,000 shares authorized,
50,138,493 and 117,348,000 shares issued and outstanding at
December 31, 2014 and December 31, 2013, respectively.		50,138		117,348
Additional paid in capital		1,274,202		586,199
Accumulated deficit		(2,157,774)		(1,804,909)
Total shareholders' deficit		(833,434)		(1,101,362)
Total liabilities and shareholders' deficit	$	104,728	$	105,973

The accompanying notes are an integral part of these financial statements

F- 3

TECHNOLOGY APPLICATIONS INTERNATIONAL CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
	Year Ended December 31,
	2014	2013
Revenues	$ 94,096	$ 51,559
Cost of revenues	83,304	26,805
Gross profit	10,792	24,754
Expenses
General and administrative	697,997	554,460
Loss From Operation	(687,205)	(529,706)
Other income (expense)
Gain on derivative valuation	700,279	64,232
Derivative expense	(267,253)	-
Gain on forgiveness of debts	-	1,000
Interest expense	(98,686)	(251,072)
Total other income (expense)	334,340	(185,840)
Net loss	$ (352,865)	$ (715,546)
Loss per share
Basic and diluted	($0.00)	($0.01)
Weighted average number of shares
Basic and diluted	94,507,750	117,248,274

The accompanying notes are an integral part of these financial statements

F- 4

TECHNOLOGY APPLICATIONS INTERNATIONAL CORPORATION AND SUBSIDIARIES (CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT For the Period from Inception (October 14, 2009) to December 31, 2013
			Additional
	Common Stock		Paid-in	Accumulated
	Shares	Amount	Capital	Deficit	Total
Balance, December 31, 2012	117,248,000	117,248	505,220	(1,089,363)	(466,895)
Shares issued from conversion of convertible notes	100,000	100	80,979		81,079
Net Loss				(715,546)	(715,546)
Balance, December 31, 2013	117,348,000	$ 117,348	$ 586,199	$ (1,804,909)	$ (1,101,362)
Shares issued for cash	815,963	816	200,619		201,435
Shares issued from exercising of warrants	34,000	34	52,666		52,700
Shares issued from conversion of convertible notes	607,149	607	446,718		447,325
Shares purchase back by notes payable issuance	(67,666,619)	(67,667)	(12,000)		(79,667)
Shares purchase back by cash	(1,000,000)	(1,000)	-		(1,000)
Net Loss				(352,865)	(352,865)
Balance, December 31, 2014	$ 50,138,493	$ 50,138	$ 1,274,202	$ (2,157,774)	$ (833,434)

The accompanying notes are an integral part of these financial statements

F- 5

TECHNOLOGY APPLICATIONS INTERNATIONAL CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
	Year ended December 31, 2014	Year ended December 31, 2013
Cash flows from operating activities
Net loss	$ (352,865)	$ (715,546)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on derivative valuation	(700,279)	(64,232)
Derivative expense	267,253	-
Gain on forgiveness of debts	-	(1,000)
Amortization of discount on convertible debentures	75,901	228,642
Depreciation and amortization	6,695	4,200
Shares issued for services rendered		-
Change in current assets and current liabilities:
Inventory	66,031	54,546
Deposits	-	43,000
Other current assets	(3,536)	1,905
Accounts payable and accrued expenses	144,302	150,521
Other current liabilities	2,713	-
Net cash used in operating activities	(493,785)	(297,964)
Cash flows from investing activities
Purchase of equipment	(18,335)	(10,000)
Payment in intangible assets	(15,000)	-
Net cash used in investing activities	(33,335)	(10,000)
Cash flows from financing activities
Advances from (to) affiliate, net	152,939	131,968
Repayment of loan from affiliate	(119,672)	(63,810)
Proceeds from issuance of convertible debentures	-	124,000
Payment of common stock purchase back	(1,000)
Proceeds from issuance of common stock	529,463	-
Net cash provided by financing activities	561,730	192,158
Net change in cash and cash equivalents	34,610	(115,806)
Cash and cash equivalents, beginning balance	4,891	120,697
Cash and cash equivalents, ending balance	$ 39,501	$ 4,891
Supplemental disclosure of cash flow information
Income taxes paid	$ -	$ -
Interest paid	$ -	$ -
Non-cash transactions
Issuance notes payable for common stock buyback	$ 79,667	$ -
Issuance of common stock for convertible notes converted	$ 447,325	$ -
Issuance of common stock for conversion of warrants	$ 52,700	$ -

The accompanying notes are an integral part of these financial statements

F- 6

TECHNOLOGY APPLICATIONS INTERNATIONAL CORPORATION AND SUBSIDIARIES

(Notes to the Consolidated Financial Statements)

1.

Nature of Operations and Basis of Presentation

Nature of Operations

Technology Applications International Corporation (“Technology”) was incorporated on October 14, 2009 under the laws of Florida.  Rejuvel Int’l, Inc. and NueEarth, Inc., Technology’s wholly owned subsidiaries and Technology, collectively, are referred to here-in as the “Company”.  The Company is engaged in developing market entry technology products and services into early and mainstream technology products and services.  Through our subsidiaries, we are focused on developing and manufacturing a line of technologically advanced skin care products and providing environmental management solutions that use electron particle accelerator technology.

Principles of Consolidation

The consolidated financial statements include the accounts of Technology Applications International Corporation and its wholly owned subsidiaries, Rejuvel Int’l, Inc. and NueEarth, Inc.  All significant inter-company accounts and transactions have been eliminated in consolidation.

Basis of Presentation and Going Concern Considerations

The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) applicable to a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Realization values may be substantially different from carrying values as shown and these financial statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs.  The Company’s ability to continue as a going concern is highly dependent upon management’s ability to increase near-term operating cash flows and obtain additional working capital through the issuance of debt and or equity.

Management intends to finance operating costs over the next twelve months with existing cash on hand, from the issuance of common shares, and additional related party borrowings.  The Company's future operations are dependent upon external funding and its ability to execute its business plan, realize sales and control expenses.  Management believes that sufficient funding will be available from additional borrowings and private placements to meet its business objectives including anticipated cash needs for working capital, for a reasonable period of time. However, there can be no assurance that the Company will be able to obtain sufficient funds to continue the development of its business operation, or if obtained, upon terms favorable to the Company. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

Development Stage Risk

Since its inception, the Company has been dependent upon the receipt of capital investment to fund its operating activities.  In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plans will be successfully executed.  The Company’s ability to execute its business plans is dependent on its ability to obtain additional debt and equity financing and achieving a profitable level of operations.  There can be no assurance that sufficient financing will be obtained or that we will achieve a profitable level of operations.

F- 7

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and their reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

Risks and Uncertainties

The Company is subject to substantial risks from, among other things, intense competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements and limited operating history.

Contingencies

Certain conditions may exist as of the date the consolidated financial statements are issued which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur.  The Company's management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment.  In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company's legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be provided for in the Company's consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.

There were no contingencies which could be evaluated at December 31, 2014.

Cash and Cash Equivalents

Cash and cash equivalents consist of highly-liquid investments with a maturity of less than three months when purchased.

Inventories

Inventories are stated at the lower of cost or market value using the FIFO (first-in, first-out) method.

The Company maintains a reserve for the inventory based on the estimated losses that result from inventory that becomes obsolete or for which the Company has excess inventory levels as of period end.  In determining these estimates, the Company performs an analysis on current demand and usage for each inventory item over historical time periods.  Based on that analysis, the Company reserves a percentage of the inventory amount within each time period based on historical demand and usage patterns of specific items in inventory.

Machinery and Equipment

Machinery and equipment are recorded at cost.  Expenditures for maintenance and repairs are charged to earnings as incurred whereas additions, renewals and betterments are capitalized.  When machinery and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations.  Depreciation of machinery and equipment is provided using the straight-line method over the assets estimated useful lives of approximately 5 to 7 years.  Leasehold improvements, if any, are amortized on a straight-line basis over the term of the lease or the estimated useful lives, whichever is shorter.

F- 8

Intangible Assets

Intangible consist of trademarks and licenses (Trademarks have a 20 year life and licenses have a 7 year life.) which are being amortized using the straight-line method over their estimated period of benefit.  We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists.  All of our intangible assets are subject to amortization.  No impairments of intangible assets have been identified during any of the periods presented.

2015	2,252
2016	2,252
2017	2,252
2018	2,252
2019	2,252
Thereafter	4,599

Amortization expense for the years ended December 31, 2014 and 2013 was $1,082 and $109, respectively.

Long-Lived Assets

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of definite-lived assets to be held and used is measured by comparison of the carrying amount of an asset to future undiscounted cash flow expected to be generated by the asset.  If such assets are impaired, the impairment is recognized as the amount by which the carrying amount exceeds the estimated future cash flows.  Assets to be sold are reported at the lower of the carrying amount or the fair value less costs to sell.  Indefinite-lived assets are tested for impairment annually or when impairment is suspected by a comparison of the carrying amount of the asset to the net present value of future cash flows expected to be generated by the asset.  There were no impaired assets at December 31, 2014.

Revenue Recognition

The Company's revenue recognition policies are in compliance with Staff Accounting Bulletin No. 104, "Revenue Recognition."  Sales revenue which has been insignificant to December 31, 2014, is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectability is reasonably assured.  Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue.

Research and Development Costs

Research and development costs, which relate primarily to the development, design and testing of products, are expensed as incurred.  Such costs were approximately $6,563 and $8,319 for the years ended December 31, 2014 and 2013, respectively.

Advertising and Marketing

Advertising and marketing expenses are expensed as incurred.  Expense recorded for the years ended December 31, 2014 and 2013 were approximately $102,886 and $86,442, respectively.

F- 9

Fair Value of Financial Instruments

In accordance with FASB ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

In determining fair value, the Company uses various valuation approaches.  In accordance with GAAP, a fair value hierarchy for inputs is used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.  Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company.  Unobservable inputs reflect the Company’s assumptions about the inputs market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.  The fair value hierarchy is categorized into three levels based on the inputs as follows:

·  Level 1 — Inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.

·  Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.

·  Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

As of December 31, 2014 and December 31, 2013, the derivative liabilities amounted to $48,851 and $349,940, respectively.  In accordance with the accounting standards, the Company determined that the carrying value of these derivatives approximated the fair value using the level 2 inputs.

Derivative Financial Instruments

Derivative financial instruments, as defined in Financial Accounting Standards, consist of financial instruments or other contracts that contain a notional amount and one or more underlying components (e.g. interest rate, security price or other variable), require no initial net investment and permit net settlement.  Derivative financial instruments may be free-standing or embedded in other financial instruments.  Further, derivative financial instruments are initially, and subsequently, measured at fair value and recorded as liabilities or, in rare instances, assets.  The Company generally does not use derivative financial instruments to hedge exposures to cash-flow or market or foreign-currency risks.  However, the Company has entered into various types of financing arrangements to fund its business capital requirements, including convertible debt and other financial instruments indexed to the Company’s own stock.  These contracts require careful evaluation to determine whether derivative features embedded in host contracts require bifurcation and fair value measurement or, in the case of freestanding derivatives (principally warrants) whether certain conditions for equity classification have been achieved.  In instances where derivative financial instruments require liability classification, the Company is required to initially, and subsequently, measure such instruments at fair value.  Accordingly, the Company adjusts the fair value of these derivative components at each reporting period through a charge to income until such time as the instruments acquire classification in stockholders’ equity. See Note 8 for additional information.

As previously stated, derivative financial instruments are initially recorded at fair value and subsequently adjusted to fair value at the close of each reporting period.  The Company estimates fair values of derivative financial instruments using various techniques (and combinations thereof) that are considered to be consistent with the objective measuring fair values.  In selecting the appropriate technique, management considers, among other factors, the nature of the instrument, the market risks that it embodies and the expected means of settlement.  For less complex derivative instruments, such as free-standing warrants, the Company uses the Black-Scholes-Merton option valuation technique because it embodies all of the requisite assumptions (including trading volatility, dividend yield, estimated terms and risk free rates) necessary to fair value these instruments.  Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors.  In addition,

F- 10

option-based techniques are highly volatile and sensitive to changes in the trading market price of our common stock, which has a high-historical volatility.  Since derivative financial instruments are initially, and subsequently, carried at fair values, our income (loss) will reflect the volatility in these estimate and assumption changes.

Income Taxes

Income taxes are accounted for under the asset and liability method.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income during the period that includes the enactment date.  The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained.  Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized.  Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.  The Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses.  No interest expense or penalties have been assessed as of, and for the years ended, December 31, 2014 and 2013.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash accounts.  The Company places its cash in what it believes to be credit-worthy financial institutions.  Accounts at each financial institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000.  At December 31, 2014 and 2013, the Company’s cash balances did not exceed federally insured limits.

Earnings (Loss) Per Common Share

The Company computes earnings per share in accordance with ASC 260, Earnings Per Share (“ASC 260”).  Basic earnings (loss) per share are computed by dividing the net income (loss) for the period by the weighted average number of common shares outstanding during the period.  Diluted earnings per share adjusts basic earnings per share for the effects of stock options and other potentially dilutive financial instruments, only in the periods in which the effects are dilutive.  

For the years ended December 31, 2014 and 2013, there were warrants to purchase 189,963 shares and 100,000 shares, respectively, of common stock that were excluded from the diluted earnings per share computation because the impact of the assumed exercise of such warrants would have been anti-dilutive, based on the fact that their exercise price exceeded the market price of the common stock as of December 31, 2014 and 2013.

Recent Accounting Pronouncements

On June 10, 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-10 (ASU 2014-10), Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. ASU 2014-10 eliminates the requirement to present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclosure the risks and uncertainties related to their activities. ASU 2014-10 also eliminates an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The presentation and disclosure requirements in Topic 915 will no longer be required for interim and annual reporting periods beginning after December 15, 2014, and the revised consolidation standards will take effect in annual periods beginning after December 15, 2015. Early adoption is permitted. The Company adopted the provisions of ASU 2014-10 effective for its financial statements for the interim period ended September 30, 2014. The adoption of ASU 2014-10 did not have any effect on the Company’s financial statement presentation or disclosures.

F- 11

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by us as of the specified effective date.  Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position or results of operations upon adoption.

2.  Major Customers

Two customers accounted for approximately 74% and 70% of total sales for the years ended December 31, 2014 and 2013, respectively.

3.  Commitments and Contingencies

The Company leases its corporate office space under a month to month lease.

On September 10, 2014, the Company signed the office lease agreement. Commencement date is October 1, 2014 and lease term is 26 months. Monthly rental fee is $3,297 plus tax. The rent for October and November 2014 are free. Security deposit is $3,297 plus tax, which is $3,537. The first month for December 2014 and the last month rent are paid in 2014 amounting $7,056. Rental payment will be $42,333 in 2015 and $38,806 in 2016.

Rent expense was approximately $16,034 and $4,194 for the years ended December 31, 2014 and 2013, respectively.

During August 2012, the Company entered into a two-year commission agreement whereby it will pay a $35 commission for each product sold.  The agreement will automatically renew in one-year increments unless cancelled in writing sixty-days prior to expiration.

As of December 31, 2014 and through the date of these financial statements, the Company has no insurance policies in place.  As of the date of these financial statements, the Company has not been advised of any liability or claims against it.

4.  Inventories

Inventories, as of December 31, 2014 and 2013, consisted of the following:

	December 31,
		2014		2013
Raw materials	$	-	$	-
Work-in-process		-		-
Finished goods		4,831		70,862
Total Inventories, net	$	4,831	$	70,862

No reserves for inventory have been deemed necessary at December 31, 2014 and 2013.

F- 12

5.  Machinery and Equipment

Machinery and equipment, as of December 31, 2014 and December 31, 2013, consisted of the following:

	Estimated Useful Lives	December 31, 2014	December 31, 2013
Computer Equipment	3 Years	$ 5,980	$ 4,162
Machinery and equipment	5 Years	29,935	13,418
Furniture and fixtures	7 Years	14,073	14,074
Accumulated depreciation		(17,896)	(12,283)
		$ 32,092	$ 19,371

Depreciation expense for the years ended December 31, 2014 and 2013 was $5,614 and $4,091, respectively.

6.  Convertible Debenture

During December 2011, the Company received $100,000 as a deposit for entering into a distribution agreement.  On March 22, 2012, the Company converted the $100,000 deposit into a convertible debenture.  The convertible debenture bears interest at a rate of five-percent (5%) per annum and was payable March 21, 2014.  At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share.  In addition to the common stock, the Holder received warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share.  These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise. In December 2013, the Noteholder elected to convert $25,000 into 50,000 shares of the Company’s Common Stock at $0.50 per share.  In February 2014, the Noteholder elected to convert $84,143 (including accrued interest of $9,143) into 168,285 shares of the Company’s Common Stock at $0.50 per share. The Company issued 218,285 warrants to purchase a 218,285 shares of common stock exercisable at $1.00 per share. As of December 31, 2014, 218,285 warrants are expired.

On September 25, 2012, the Company issued a $100,000 convertible debenture.  The convertible debenture bears interest at a rate of five-percent (5%) per annum and was payable September 20, 2013.  At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share.  In addition to the common stock, the Holder received warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share.  These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise. This convertible debenture extended 360 days on September 21, 2013. In December 2013, the Noteholder elected to convert $25,000 into 50,000 shares of the Company’s Common Stock at $0.50 per share.  In February 2014, the Noteholder elected to convert $88,273 (including accrued interest of $13,273) into 176,515 shares of the Company’s Common Stock at $0.50 per share. The Company issued 226,515 warrants to purchase a 226,515 shares of common stock exercisable at $1.00 per share. As of December 31, 2014, 226,515 warrants are expired.

On April 3, May 23, May 31, June 10, July 29, August 14, and September 25, 2013 the Company issued $5,000, $10,000, $10,000, $25,000, $4,000, $50,000 and $20,000 convertible debentures, respectively.  The convertible debentures bear interest at a rate of ten-percent (10%) per annum and is payable March 29, May 18, May 26, June 5, July 24, August 9, and September 20, 2014, respectively.  At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share.  In addition to the common stock, the Holder shall receive warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share.  These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise. In February 2014, the Noteholder elected to convert $110,866 (including accrued interest of $6,866) into 220,785 shares of the Company’s Common Stock at $0.50 per share. The Company issued 220,785 warrants to purchase 220,785 shares of common stock exercisable at $1.00 per share. In April 2014, the Noteholder elected to convert $21,534 (including accrued interest of $1,534) into 41,534 shares of the

F- 13

Company’s Common Stock at $0.50 per share. The Company issued 41,534 warrants to purchase 41,534 shares of common stock exercisable at $1.00 per share. As of December 31, 2014, 262,319 warrants are expired.

The Compound derivative comprises certain derivative features embedded in the host convertible debenture contracts including the conversion feature and warrants both of which contain anti-dilution protections.  These instruments were combined into one compound derivative and bifurcated from the host instrument at fair value.  The Company applied the Black-Scholes Merton valuation technique to fair value these derivatives because this technique embodies all of the assumptions necessary to fair value these compound derivative instruments.  Since the derivative financial instruments are required to be recorded, both initially, and subsequently, at fair value, there were insufficient proceeds to allocate any amount to the convertible debentures and, accordingly, it has no carrying value on the date of inception.  Additionally, proceeds were insufficient to record the fair values of the derivative financial instruments, resulting in initial interest expense of $267,253.  It should be noted that the derivative instruments will be adjusted to fair value at each reporting date.  As the Company does not have historical volatility data for its own stock, the expected volatility was based upon the Company’s peer group in the industry in which it does business.  Fair values are highly influenced by the trading stock price and volatility of the peer group, changes in our credit risk and market interest rates. The company amortizes the discount on the convertible debentures resulting from the initial allocation over the term of the convertible debt instruments using the effective method.  Amortization expense arising from this method for the years ended December 31, 2014 and 2013 amounted to $75,901 and $182,197 which have been included as a component of interest expense. For the year ended December 31, 2014, gain on derivative valuation was $700,279 (For the year ended December 31, 2013, gain on the derivative valuation was $64,232)

7.  Common Stock

In December 31, 2013, the Company issued 100,000 shares of its common stock at $0.50 for conversion of convertible debenture of $50,000. Also, the Company issued 100,000 warrants to purchase a 100,000 shares of common stock exercisable at $1.00 per share.

In February 2014, the Company issued 565,615 shares of its common stock at $0.50 for conversion of convertible debentures of $254,000 and 29,282 of accrued interest.

In March 2014, the Company issued 601,000 shares of its common stock at $0.50 through a private placement for total cash consideration of $300,500. Also, the Company issued 601,000 warrants to purchase to purchase 601,000 shares of common stock exercisable at $1.00 per share.

On April 3, 2014, the Company entered stock subscription agreement of 5,000 shares at $1.00 per share with 5,000 warrants to purchase 5,000 shares of common stock with an exercise price of $2.00 per share.  These warrants expired 180 days after stock issuance date.

On April 8, 2014, the Company issued 41,534 shares of its common stock at $0.50 for conversion of a convertible debenture of $20,000 and $1,534 of accrued interest.

On April 16, 2014, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 20,000 warrants to purchase 20,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expired 180 days after stock issuance date.

On July 7, and July 31, 2014, the Company entered stock subscription agreements of 50,000 shares and 20,000 shares at $1.00 per share with 50,000 and 20,000 warrants to purchase 50,000 and 20,000 shares of common stock with an exercise price of $2.00 per share.  These warrants expire 360 days after stock issuance date.

On August 22, 2014, the Company entered stock subscription agreement of 99,963 shares at $1.00 per share with 99,963 warrants to purchase 99,963 shares of common stock with an exercise price of $2.00 per share.  These warrants expire 360 days after stock issuance date.

F- 14

On August 28, 2014, the Company authorized the purchase of 64,666,619 shares of common stock from affiliate at $0.001 per share and signed a promissory note for a total of $64,667 to affect the purchase. The Company then cancelled the shares.

On August 28, 2014, the Company authorized the purchase of 3,000,000 shares of common stock from shareholder at $0.005 per share and signed a promissory note for a total of $15,000 to affect the purchase. The Company then cancelled the shares.

On September 9, 2014, a Warrant holder exercised 34,000 warrants to purchase 34,000 restricted common shares at a price of $1.00 per share.

On August 28, 2014, the Company authorized the purchase of 1,000,000 shares of common stock from shareholder at $0.001 per share and paid by cash $1,000 to affect the purchase. The Company then cancelled the shares.

On December 28, 2014, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 20,000 warrants to purchase 20,000 shares of common stock with an exercise price of $2.00 per share.  These warrants expire 360 days after stock issuance date.

Due to a ratchet provision, the warrants issued during 2014 were accounted for as a derivative and fair valued using the Black Scholes valuation model. The initial valuation was $561,281.

Stock Purchase Warrants

In conjunction with the Private Placement Memorandum dated February 13, 2013, the Company is offering up to 3,000,000 units.  Each unit consists of 1 share of common stock priced at $1.00 and one Class A Warrant to purchase 1 share of common stock with an exercise price of $1.50 per share.  These warrants expire on the earlier of (i) 180 days after the common stock commences quotation on the OTC Bulletin Board or (ii) one year after the date of issuance. No issuances have been sold from this offering as of December 31, 2014.

In December 2013, Noteholders elected to convert $50,000 into 100,000 shares of the Company’s Common Stock at $0.50 per share.  The Company issued 100,000 warrants to purchase 100,000 shares of common stock exercisable at $1.00 per share.  The warrants were expired as of December 31, 2014.

In February and April 2014, the Noteholder elected to convert $304,816 (including accrued interest of $30,816) into 607,149 shares of the Company’s Common Stock at $0.50 per share.  The Company issued 607,149 warrants to purchase a 607,149 shares of common stock exercisable at $1.00 per share. The warrants were expired as of December 31, 2014.

In March 2014, the Company issued 601,000 shares of its common stock at $0.50 through a private placement for total cash consideration of $300,500. Also, the Company issued 601,000 warrants to purchase 601,000 shares of common stock exercisable at $1.00 per share. 34,000 warrants were exercised in September 2014 and 567,000 warrants were expired as of December 31, 2014.

On April 3, 2014, the Company entered stock subscription agreement of 5,000 shares at $1.00 per share with 5,000 warrants to purchase 5,000 shares of common stock with an exercise price of $2.00 per share.  These warrants expire 180 days after stock issuance date. The warrants were expired as of December 31, 2014.

On April 16, 2014, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 20,000 warrants to purchase 20,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 180 days after stock issuance date. The warrants were expired as of December 31, 2014.

.

On July 7, and July 31, 2014, the Company entered stock subscription agreements of 50,000 shares and 20,000 shares at $1.00 per share with 50,000 and 20,000 warrants to purchase 50,000 and 20,000 shares of common stock with an exercise price of $2.00 per share.  These warrants expire 360 days after stock issuance date. As of December 31, 2014, 50,000 and 20,000 warrants are not exercised or expired.

F- 15

On August 22, 2014, the Company entered stock subscription agreement of 99,963 shares at $1.00 per share with 99,963 warrants to purchase 99,963 shares of common stock with an exercise price of $2.00 per share.  These warrants expire 360 days after stock issuance date.  As of December 31, 2014, 99,963 warrants are not exercised or expired.

On December 28, 2014, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 20,000 warrants to purchase 20,000 shares of common stock with an exercise price of $2.00 per share.  These warrants expire 360 days after stock issuance date. As of December 31, 2014, 20,000 warrants are not exercised or expired

The following table summarizes all warrant activity for the years ended December 31, 2014 and 2013:

	Shares	Weighted-Average Exercise Price Per Share	Remaining term	Intrinsic value
Outstanding, December 31, 2013	100,000	1.00
Exercisable at December 31, 2013	100,000	1.00
Granted	1,423,112	1.16
Exercised	(34,000)	1.00
Expired	(1,299,149)	1.04	0.79 year	$ 0
Exercisable at December 31, 2014	189,963	2.00	0.79 year	$ 0

8.

Fair Value Measurements

On a recurring basis, we measure certain financial assets and liabilities based upon the fair value hierarchy as described in the Company’s significant accounting policies in Note 1.  The following table presents information about the Company’s liabilities measured at fair value as of December 31, 2014

	Level 1	Level 2	Level 3	Fair Value at December 31, 2014
Liabilities
Derivative liability	-	$ 48,851	-	$                  48,851

	Level 1	Level 2	Level 3	Fair Value at December 31, 2013
Liabilities
Derivative liability	-	$ 349,940	-	$                  349,940

The fair value changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), relate solely to the derivative liability as follows:

Balance at December 31, 2013	349,940
Adjustment due to conversions	(141,294)
Adjustment due to exercise warrant	(18,700)
New warrant issued with stock	559,184
Fair value adjustment	(700,279)
Balance at December 31, 2014	$ 48,851

F- 16

9. Derivative Financial Instruments

The balance sheet caption derivative liability consists of derivative features embedded in convertible debentures including the conversion feature and warrants which have anti-dilution protections.  These derivative financial instruments are indexed to an aggregate of 189,963 shares of the Company’s common stock as of December 31, 2014 and are carried at fair value.  The balance at December 31, 2014 and 2013 was $48,851 and $349,940, respectively.

The valuation of the derivative liability is determined using a Black-Scholes Merton Model because that model embodies all of the relevant assumptions that address the features underlying these instruments.  Significant assumptions used in the Black-Scholes models at December 31, 2014 include the following:

Risk-free interest rate	0.25%
Estimated volatility	186%
Dividend rate	None
Estimated term in years	0.5-1.1

10. Income Taxes

Deferred income taxes for 2014 and 2013 were provided for the temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities.  The effects of temporary differences and carry-forwards at December 31, 2014 and 2013 are as follows:

Deferred tax assets:		December 31, 2014		December 31, 2013
Net operating loss carry-over	$	733,642	$	613,669
Derivative liability		(286,182)		(48,097)
Common stock issued for services rendered		3,848		3,848
Interest on derivative		242,693		151,827
Valuation allowance		(773,283)		(506,081)
Deferred tax assets per books	$	-	$	-

The income tax provision differs from the amount of income tax determined by applying the estimated U.S. federal and state income tax rates of 34 percent to pretax income from continuing operations for the year ended December 31, 2014 and 2013 due to the following:

		December 31, 2014		December 31, 2013
Income tax expense at statutory rate	$	(119,974)	$	(243,286)
Gain (loss) on derivative valuation		(238,095)		(21,839)
Common stock issued for services rendered		-		-
Interest on derivative		90,866		77,398
Valuation allowance		267,203		187,727
Income tax expense per books	$	-	$	-

As of December 31, 2014, the Company had net operating loss carry forwards for income purposes of approximately $733,643 ($613,669 as of December 31, 2013) that may be offset against future taxable income.  The net operating loss carry-forwards expire through the year 2034.  Current tax laws limit the amount of loss available to be offset against future taxable income when a substantial change in ownership occurs or a change in the nature of the business.  Therefore, the amount available to offset future taxable income may be limited.

F- 17

No tax benefit has been reported in the consolidated financial statements for the realization of loss carry-forwards, as the Company believes there is high probability that the carry-forwards will not be utilized in the foreseeable future.

11.  Related Parties

An affiliate of the Company, the Company’s president, has been funding operations of the Company by making payments directly to third parties or advancing monies to the Company.  These amounts bear no interest and are payable on demand.  Amounts advanced to the Company during the years ended December 31, 2014 and 2013 were approximately $152,938 and $131,968, respectively.  Payments of approximately $119,672 and $63,810 were made during the years ended December 31, 2014 and 2013, respectively, resulting in amounts due to the affiliate at December 31, 2014 and 2013 are approximately $270,747 and $237,480, respectively.

During June 2012, the Company borrowed $125,000 from an affiliate.  The loan bears interest at 10% per annum and is unsecured and payable upon demand. The Company has paid $0 toward the loan amount during 2014. The outstanding balance as of December 31, 2014 is $77,401 and accrued interest of $23,845.

On August 28, 2014, the Company authorized the purchase of 64,666,619 shares of common stock from affiliate at $0.001 per share and signed an unsecured promissory note for a total of $64,667 to affect the purchase. The loan bears interest at 6% per annum and is unsecured and payable upon demand.  The Company has paid $0 towards the loan amount during 2014.  The outstanding balance as of December 31, 2014 is $64,667. During 2014, the Company accrued the interest $1,329.

On August 28, 2014, the Company authorized the purchase of 3,000,000 shares of common stock from shareholder at $0.005 per share and signed a promissory note for a total of $15,000 to affect the purchase. The loan bears interest at 6% per annum and is unsecured and payable upon demand.  The Company has paid $0 towards the loan amount during 2014.  The outstanding balance as of December 31, 2014 is $15,000. During 2014, the Company accrued the interest $308.

The Company periodically rents a recreational vehicle from an affiliate of the Company, an entity owned by the Company’s president, which is utilized for advertising and promotional events.  The Company is charged $1,729 for each month of use and is payable in arrears.  For the years ended December 31, 2014 and 2013, the Company recorded expense of approximately $3,237 and $1,052, respectively.  

12.  Significant Agreement

On September 30, 2013, the Company and its wholly-owned subsidiary Rejuvel Int’l, Inc., Florida corporations (the “Company”) entered into a partially exclusive Co-License Agreement (the “License Agreement”) by and amongst the National Aeronautics and Space Administration, an agency of the United States (“N.A.S.A.”) and the Administrators of the Tulane Educational Fund (“Tulane University”) for the use of U.S. Patent No. 6,730,498 B1, an invention entitled “Production of Functional Proteins: Balance of Shear Stress and Gravity,” which was issued on May 4, 2004 (the “Patent”). The company currently uses the Patent process to develop our anti-aging skin creams and shampoos. The License Agreement permits the Company to use the Patent as well as the name N.A.S.A., with its products, as per the terms of the License Agreement.

On July 25, 2014, Technology Applications International Corporation and its wholly-owned subsidiary Rejuvel Int’l, Inc., Florida corporations (the “Company”) entered into an exclusive License Agreement (the “License Agreement”) by and between the National Aeronautics and Space Administration, an agency of the United States (“N.A.S.A.”) for the use of U.S. Patent No.’s 6,485,963 B1, an invention entitled “Growth Stimulation Of Biological Cells and Tissue By Electromagnetic Fields and Uses Thereof” which was filed on June 2, 2000, and U.S. Patent No. 6,673,597 B2, for an invention entitled “Growth Stimulation of Biological Cells and Tissue By Electromagnetic Fields and Uses Thereof, which was filed on February 28, 2001 (the “Patents”). We currently use the Patents process to develop our anti-aging skin creams and shampoos. The License Agreement permits the

F- 18

Company to use the Patents as well as the name N.A.S.A., with its products, as per the terms of the License Agreement.

In consideration of the grant of the License Agreement, the Company will pay a 3% royalty to N.A.S.A. on the gross sales of any royalty-base products. The License agreement further requires the Company to remit to N.A.S.A. a non-refundable license fee in the amount of Fifteen Thousand Dollars ($15,000) upon the execution of the License Agreement and then another Fifteen Thousand Dollars ($15,000) is due six months after the license commencement date. The Company also agrees to pay N.A.S.A. a minimum royalty of Fifteen Thousand Dollars ($15,000), at the end of each accounting period (“Accounting Period”). The Accounting Period shall begin at the end of the second Accounting period of the License Agreement and each Accounting period thereafter.

The License Agreement requires that the Company achieve a practical application of the Patent within eighteen (18) months from the commencement date of the License Agreement. In accordance with the appendix to the License Agreement; wherein it states that by August 2014, the Company shall have tested the product to meet federal, state and international regulations of its skin cream products, by October 2014, the Company shall have packaged and filled five products and by December 2014, the Company shall have Domestic and International distribution of five products. Once a practical application is achieved the term of the agreement shall be equal to the unexpired term of the last patent to be in effect of the patent(s) encompassed under the Patents.  The Company further agrees that any products using the Patents process shall be substantially manufactured in the United States.  As of the Date of this filing all milestones associated with the License Agreement have been completed on time and to the satisfaction of the License Agreement Parties.

On October 4, 2013, the Company terminated its distribution agreement (“Distribution Agreement”) by and between the Company and Regenetech, Inc., a Texas corporation, pursuant to the termination clauses contained within the Distribution Agreement.  Regenetech, Inc., was in a material breach of contract of the Distribution Agreement, because Regenetech, Inc., failed to upkeep its license requirements with N.A.S.A. and the Tulane University in order to maintain the license in good standing.  Due to the material breach of contract by Regenetech, Inc., the termination of the Distribution Agreement does not contain any early termination penalties to the Company.

13.  Subsequent Events

On January 27, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of 1.00 per share.  These warrants expire 360 days after stock issuance date.

On February 2, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 360 days after stock issuance date.

On February 2, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 360 days after stock issuance date.

On February 3, 2015, the Company entered stock subscription agreement for 21,600 shares at $0.50 per share.

On February 18, 2015, the Company entered stock subscription agreement of 50,000 shares at $0.50 per share with 50,000 warrants to purchase 50,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 360 days after stock issuance date.

On February 18, 2015, the Company entered a consulting agreement whereby the Company issued 15,000 shares for consulting services, on a month to month basis.

On February 19, 2015, the Company entered a consulting agreement whereby the Company issued 25,000 shares for consulting services, on a month to month basis.

F- 19

On February 21, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 360 days after stock issuance date.

On February 21, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 360 days after stock issuance date.

On February 21, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 360 days after stock issuance date.

On February 23, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 360 days after stock issuance date.

On or about February 26, 2015, the Company entered into a distribution agreement (“Distribution Agreement”) with Yontem Cosmetics Dis Tic. Ltd. Sti (“Yontem”) a Turkish company; thereby, naming Turkey (the “Territory”) as an exclusive territory for Yontem.  The terms of the Distribution Agreement, expects that Yontem will sell a minimum of 1,000 1.7oz units per month during the 1^st year, 2,000 1.7oz units per month during the second year of operation and 3,000 units per month in the third year upon the establishment of the company by Yontem. The Distribution Agreement is for an initial period of three years and then the two parties will evaluate the progress of the Distribution Agreement. The Distribution Agreement can then be renewed for an additional five-five year periods. The Distribution Agreement also states that in order to maintain exclusivity on the Territory the quota numbers must be met, and that if they are not met then Yontem will lose exclusivity to the Territory.

On March 6, 2015, the Company entered a service agreement whereby the Company issued 15,000 shares for marketing solution and strategy services, on a month to month basis.

On March 10, 2015, the Company entered stock subscription agreement of 50,000 shares at $0.50 per share with 50,000 warrants to purchase 50,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 360 days after stock issuance date.

On March 10, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 360 days after stock issuance date.

On March 14, 2015, the Company entered an independent contractor agreement whereby the Company issued 100,000 shares for medical services, for a period of one year.

On March 14, 2015, the Company entered an independent contractor agreement whereby the Company issued 10,000 shares for medical services, for a period of one year.

Pursuant to Accounting Standards Codification 855-10, the Company has evaluated all events or transactions that have occurred from December 31, 2014 through the filing with the SEC.  

F- 20

ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

None.

ITEM 9A. CONTROLS AND PROCEDURES.

Management’s Report on Internal Control over Financial Reporting

This report includes the certifications of our Chief Executive Officer and Chief Financial Officer required by Rule 13a-14 of the Securities Exchange Act of 1934 (the “Exchange Act”). See Exhibits 31.1 and 31.2. This Item 9A includes information concerning the controls and control evaluations referred to in those certifications.

Evaluation of Disclosure Controls and Procedures

Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company. Management identified certain material weaknesses which together with remedial action taken are described below.

Disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in rules and forms adopted by the SEC, and that such information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures.

In connection with the preparation of our annual report as of December 31, 2014, the Company’s management, under the supervision and with the participation of the Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2014. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective as of December 31, 2014, as a result of the existence of material weaknesses in our internal control over financial reporting as discussed below.

Evaluation of Internal Control over Financial Reporting

Management, with the participation of our Chief Executive Officer and Chief Financial Officer, has conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework set forth in “Internal Control—Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on management’s assessment under this framework, management has concluded that our internal control over financial reporting was not effective as of December 31, 2014, as a result of the existence of material weaknesses.

A material weakness is a control deficiency (within the meaning of the Public Company Accounting Oversight Board (PCAOB) Auditing Standard No. 5) or combination of control deficiencies that result in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected.  Management has identified the following four material weaknesses which have caused management to conclude that, as of December 31, 2014, our disclosure controls and procedures and internal control over financial reporting were not effective at the reasonable assurance level:

The Company did not maintain an effective financial reporting process to prepare financial statements in accordance with U.S. GAAP. Specifically, our process lacked timely and complete financial statement reviews, appropriate account closing procedures, and appropriate reconciliation processes.

We do not have written documentation of our internal control policies and procedures.  Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act which is applicable to us as of and for the year ended December 31, 2014. Management evaluated the impact of our failure to have written documentation of our internal controls and procedures on our assessment of our

26

disclosure controls and procedures and internal control over financial reporting and has concluded that the control deficiency that resulted represented a material weakness.

The Company’s board of directors has no audit committee, independent director or member with financial expertise which causes ineffective oversight of our external financial reporting and internal control over financial reporting.

We do not have sufficient segregation of duties within accounting functions, which is a basic internal control.  Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible.  However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals.  Management evaluated the impact of our failure to have segregation of duties on our assessment of our disclosure controls and procedures and internal control over financial reporting and has concluded that the control deficiency that resulted represented a material weakness.

Changes in Internal Control over Financial Reporting

Management, with the participation of our Chief Executive Officer and Chief Financial Officer, has assessed whether any changes in our internal control over financial reporting that occurred during the year ended December 31, 2014, have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Significant changes are being implemented during the fiscal 2015 year to remediate our material weaknesses in internal control over financial reporting. Management believes that such measures we are implementing to remediate the material weaknesses in internal control over financial reporting will have a favorable impact on our internal control over financial reporting. Changes in our internal control over financial reporting through the date of this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting are described below.

Remediation Actions Relating to Material Weaknesses

Once the Company has sufficient personnel available, then our Board of Directors, in particular and in connection with the aforementioned deficiencies, will establish the following remediation measures:

Our Board of Directors plans to nominate an audit committee or a financial expert on our Board of Directors in fiscal 2015.

We will appoint additional personnel to assist with the preparation of the Company’s financial reporting process.

Conclusion

In light of the material weaknesses described below, we performed additional analysis and other post-closing procedures to ensure our financial statements were prepared in accordance with generally accepted accounting principles.  Accordingly, we believe that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented.

ITEM 9B. OTHER INFORMATION.

On October 1, 2014, the Company signed an agreement with Strawberry Bullet, LLC, a New York based advertising agency that will assist the Company’s wholly-owned subsidiary Rejuvel, with market research, and branding services for its facial cream, as well as assisting with creating a marketing and advertising campaign for our subsidiary.  

On or about October 9, 2014, The Company completed a clinical study to test the efficacy of their products at Essex Testing Clinic in Verona, New Jersey. Team members on The Essex Testing Clinic staff included doctors, nurses, clinical study, recruitment professionals, quality assurance and trained evaluators and a large network of consulting physicians, all possessing considerable experience in clinical investigation. Team personnel evaluated

27

facial imperfections of each subject and took scientific measurements to determine the firmness and elasticity of the skin to detect change.  

After 6 weeks of product use, 32 subjects responded with the following:

• 100% – Smoother and softer skin.

• 100% – Facial skin had an improved texture.

• 100% – Product regimen was gentle and non-irritating.

• 84.4% – Appearance of fine lines on face is less noticeable.

• 78.1% – Appearance of wrinkles on face is less noticeable.

• 81.3% – Improvement in the firmness/elasticity of skin.

• 75.0% – Reduction in the appearance of dark, under the eye circles.

• 84.4% – Skin appeared renewed and discolorations were reduced.

• 87.5% – Moisture content in skin had increased.

• 90.6% – Skin appears brighter and more radiant.

• 90.6% – Skin appears healthier.

• 93.8% – Skin appears refreshed.

• 87.5% – Overall appearance was improved.

Scientific Measurements results after 6 weeks of use are as follows:

• 78% of subjects Fine Lines/ Wrinkles were significantly reduced

• 88% of subjects Under Eye Discoloration significantly improved

• 78% of subjects Firmness/ Elasticity significantly improved

• 97% of subjects Skin Moisture significantly improved

The conclusion of this clinical study fulfills the requirements to be able to broadcast on the major home shopping channels.  Our next step is to voluntarily submit our testing claims to the Federal Drug Administration (FDA).

On or about October 13, 2014, the Company entered into an distribution agreement (“Distribution Agreement”) with Olgun Emirzade, who is a Director of Meditem Cyprus Limited (“Meditem”); thereby, naming Northern Cyprus as a non-exclusive territory for Meditem. The terms of the Distribution Agreement, expects that Meditem will sell a minimum of 200 units of skin cream a month for the first year, allows for Meditem to receive a finder’s fee for each 1.7oz bottle purchased by any newly referred distributor in the Republic of Cyprus. The Distribution Agreement is for a period of one year and then the two parties will evaluate the progress and the Distribution Agreement can be renewed for an additional five one year periods. The Distribution Agreement also calls for a quota to be established after the first year of the Distribution Agreement that the more territories and exclusivity to territories may be adjusted in further negotiations.

Subsequent Events

On or about February 26, 2015, the Company entered into a distribution agreement (“Distribution Agreement”) with Yontem Cosmetics Dis Tic. Ltd. Sti (“Yontem”) a Turkish company; thereby, naming Turkey (the “Territory”) as an exclusive territory for Yontem.  The terms of the Distribution Agreement, expects that Yontem will sell a minimum of 1,000 1.7oz units per month during the 1^st year, 2,000 1.7oz units per month during the second year of operation and 3,000 units per month in the third year upon the establishment of the company by Yontem. The Distribution Agreement is for an initial period of three years and then the two parties will evaluate the progress of the Distribution Agreement. The Distribution Agreement can then be renewed for an additional five-five year periods. The Distribution Agreement also states that in order to maintain exclusivity on the Territory the quota numbers must be met, and that if they are not met then Yontem will lose exclusivity to the Territory.

A copy of the Distribution Agreement is filed herewith, as Exhibit 10.11, and is incorporated herein by this reference.

28

PART III

ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS.

Identification of Directors and Executive Officers

The following table sets forth the names and ages of our current directors and executive officers:

Name	Age	Position with the Company	Director Since
Charles J. Scimeca	70	CEO, CFO, President, Treasurer, Secretary, & Director	April 12, 2010
John Stickler	46	Vice President & Director	May 18, 2012

The Board of Directors has no nominating, audit or compensation committee at this time.

Term of Office

Each director is elected by the Board of Directors and serves until his or her successor is elected and qualified, unless he or she resigns or is removed earlier. Each of our officers is elected by the Board of Directors to a term of one (1) year and serves until his or her successor is duly elected and qualified, or until he or she is earlier removed from office or resigns.

Background and Business Experience

The business experience during the past five years of the person presently listed above as an Officer or Director of the Company is as follows:

Charles J. Scimeca – Mr. Scimeca has served as our Chief Executive Officer, Chief Financial Officer, Secretary and sole director since April 2010. Since February 2003, Mr. Scimeca has served as President and Chief Executive Officer of Coast To Coast Equity Group, Inc., which provides consulting services for private companies going public, including investor relations and marketing services. Since January 1998, Mr. Scimeca has served as President and Chief Executive Officer of Coast To Coast Realty Group, Inc., which offers commercial and residential real estate services. Mr. Scimeca is a licensed real estate broker.

John Stickler – Mr. Stickler has served as Vice President and Director since May 18, 2012.  He has worked as a sales and marketing professional for over nineteen years. His experience is mainly in the corporate management of sales and in the selling of a product. From January 2007 until January 2011, Mr. Stickler was a consultant for Regenetech, Inc., whom our Company has a distribution agreement with.  While working for Regenetech, Mr. Stickler gained knowledge of the techniques necessary for manufacture and production of our cream as well as forming working relationships with the inventors of the Bio-Reactor that expands the fibroblast cells that make up the key ingredient for our cream. Mr. Stickler assisted Regenetech, Inc. in introducing their technologies and expansion services to healthcare professionals.  He test marketed the cream to individuals of both sexes with positive results. During this time period Mr. Stickler served as vice-president of Renuell, Inc. a Florida corporation that was dissolved in October of 2010. Renuell, Inc. did no business although it was formed.  No other corporations or organizations are a parent, subsidiary or other affiliate of the registrant that Mr. Stickler is or has been involved with. Because of Mr. Sticker’s knowledge of the cream from its inception and hands on relationships with N.A.S.A. and Regenetech, as well as his experience with marketing skin cream we appointed him as Vice-President and as a Director.

Identification of Significant Employees

We have no significant employees, other than Charles J. Scimeca, our President, Chief Executive Officer, and Director and John Stickler our Director.

Family Relationship

We currently do not have any officers or directors of our Company who are related to each other.

29

Involvement in Certain Legal Proceedings

During the past ten years no director, executive officer, promoter or control person of the Company has been involved in the following:

(1)

A petition under the Federal bankruptcy laws or any state insolvency law which was filed by or against, or a receiver, fiscal agent or similar officer was appointed by a court for the business or property of such person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer at or within two years before the time of such filing;

(2)

Such person was convicted in a criminal proceeding or is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses);

(3)

Such person was the subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting, the following activities:

i.

Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other person regulated by the Commodity Futures Trading Commission, or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity;

ii.

Engaging in any type of business practice; or

iii.

Engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of Federal or State securities laws or Federal commodities laws;

(4)

Such person was the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any Federal or State authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any activity described in paragraph (f)(3)(i) of this section, or to be associated with persons engaged in any such activity;

(5)

Such person was found by a court of competent jurisdiction in a civil action or by the Commission to have violated any Federal or State securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended, or vacated;

(6)

Such person was found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated;

(7)

Such person was the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of:

i.

Any Federal or State securities or commodities law or regulation; or

30

ii.

Any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or

iii.

Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or

(8)

Such person was the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

Audit Committee and Audit Committee Financial Expert

The Company does not have an audit committee or an audit committee financial expert (as defined in Item 407 of Regulation S-K) serving on its Board of Directors. All current members of the Board of Directors lack sufficient financial expertise for overseeing financial reporting responsibilities. The Company has not yet employed an audit committee financial expert on its Board due to the inability to attract such a person.

The Company intends to establish an audit committee of the Board of Directors, which will consist of independent directors. The audit committee’s duties will be to recommend to the Company’s Board of Directors the engagement of an independent registered public accounting firm to audit the Company’s financial statements and to review the Company’s accounting and auditing principles. The audit committee will review the scope, timing and fees for the annual audit and the results of audit examinations performed by the internal auditors and independent registered public accounting firm, including their recommendations to improve the system of accounting and internal controls. The audit committee will at all times be composed exclusively of directors who are, in the opinion of the Company’s Board of Directors, free from any relationship which would interfere with the exercise of independent judgment as a committee member and who possess an understanding of financial statements and generally accepted accounting principles.

Code of Ethics

Our board of directors has not adopted a code of ethics due to the fact that we presently only have one director and we are in the development stage of our operations. We anticipate that we will adopt a code of ethics when we increase either the number of our directors and officers or the number of our employees.

Compliance with Section 16(a) of the Exchange Act

Section 16(a) of the Securities Exchange Act of 1934 requires our directors and executive officers and persons who beneficially own more than ten percent of a registered class of our equity securities to file with the SEC initial reports of ownership and reports of change in ownership of common stock and other equity securities of the Company. Officers, directors and greater than ten percent stockholders are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file. Based solely upon a review of Forms 3 and 4 and amendments thereto furnished to us under Rule 16a-3(e) during the year ended December 31, 2014, Forms 5 and any amendments thereto furnished to us with respect to the year ended December 31, 2014, and the representations made by the reporting persons to us, we believe that during the year ended December 31, 2014, our executive officers and directors and all persons who own more than ten percent of a registered class of our equity securities complied with all Section 16(a) filing requirements.

31

ITEM 11. EXECUTIVE COMPENSATION

The table set forth below summarizes the annual and long-term compensation for services in all capacities to us payable to our officers and directors for the fiscal years ended December 31, 2014 and 2013. Our Board of Directors may adopt an incentive stock option plan for our executive officers that would result in additional compensation.

Summary Compensation Table

Name and Principal Position	Fiscal Year Ended 12/31		Salary ($)		Bonus ($)		Stock Awards ($)		Option Awards ($)		Non-Equity Incentive Plan Compensation ($)		Nonqualified Deferred Compensation Earnings ($)		All Other Compensation ($)		Total ($)
Charles J. Scimeca (1) President, CEO, CFO, Secretary, Treasurer and Director	2014		$	120,000		-0-		-0-		-0-		-0-		-0-		-0-		120,000
	2013		$	120,000		-0-		-0-		-0-		-0-		-0-		-0-		120,000
John Stickler Vice President, Director (1)(2)	2014	$		-0-		-0-		-0-		-0-		-0-		-0-		-0-	$	-0-
	2013	$		-0-		-0-		-0-		-0-		-0-		-0-		-0-	$	-0-

(1) The Company’s two officers and directors currently devote approximately 30-40 hours per week to manage the affairs of the Company, including, but not limited to the upkeep of Technology Applications International Corporation and the research and development associated with expanding the Company to new markets. Mr. Scimeca is the President, CEO, CFO, Secretary, Treasurer and a Director of the Company and Mr. Stickler is the Vice President and a Director of the Company.

(2) Mr. Stickler was appointed as Vice President and Director on May 18, 2012, and is not compensated as a director.

Narrative Disclosure to Summary Compensation Table

There are no compensatory plans or arrangements, including payments to be received from the Company with respect to any executive officer, that would result in payments to such person because of his or her resignation, retirement or other termination of employment with the Company, or its subsidiaries, any change in control, or a change in the person’s responsibilities following a change in control of the Company.

Outstanding Equity Awards at Fiscal Year-End

No executive officer received any equity awards, or holds exercisable or unexercisable options, as of the year ended December, 2014.

Long-Term Incentive Plans

There are no arrangements or plans in which we provide pension, retirement or similar benefits for directors or executive officers.

Compensation Committee

We currently do not have a compensation committee of the Board of Directors. The Board of Directors as a whole determines executive compensation.

32

Compensation of Directors

Our directors receive no extra compensation for their service on our Board of Directors.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

Security Ownership of Management

The following table sets forth certain information concerning the number of shares of our common stock owned beneficially as of April 15, 2014, by: (i) each of our directors; (ii) each of our named executive officers; and (iii) each person or group known by us to beneficially own more than 5% of our outstanding shares of common stock. Unless otherwise indicated, the shareholders listed below possess sole voting and investment power with respect to the shares they own.

Name and Address of Beneficial Owner	Title of Class	Amount and Nature of Beneficial Ownership (1) (#)	Percent of Class (2) (%)
Charles J. Scimeca 1001 Brickell Bay Drive, Suite 1716 Miami, FL 33131	Common	32,333,881	64.1%
John Stickler Chase Bank Building 150 SE 2nd Ave, Suite 403 Miami, FL 33131	Common	3,000,000	5.9%
All Officers and Directors as a Group (2 Persons)	Common	35,333,881	70%
D&E Global Management, Inc.(3) 276 S. Parkway Miami, FL 33160	Common	4,552,500	9.0%
International Consulting and Equity Group, Inc.(4) 1040 Biscayne Blvd, Suite 4006 Miami, FL 33132	Common	3,933,835	7.8%
(1)  The number and percentage of shares beneficially owned is determined under rules of the SEC and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares as to which the individual has sole or shared voting power or investment power and also any shares which the individual has the right to acquire within 60 days through the exercise of any stock option or other right. The persons named in the table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them, subject to community property laws where applicable and the information contained in the footnotes to this table. (1) Based on 50,473,093 issued and outstanding shares of common stock as of April 15, 2015. (2) Debra Elenson has voting and dispositive control over the common shares beneficially owned by D&E Global Management, Inc. (3) Karen Hardcastle has voting and dispositive control over the common shares beneficially owned by International Consulting and Equity Group, Inc.

Changes in Control

There are no present arrangements or pledges of the Company’s securities which may result in a change in control of the Company.

33

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

Related Party Transactions

An affiliate of the Company, the Company’s president, has been funding operations of the Company by making payments directly to third parties or advancing monies to the Company.  These amounts bear no interest and are payable on demand.  Amounts advanced to the Company during the years ended December 31, 2014 and 2013 were approximately $152,938 and $131,968, respectively.  Payments of approximately $119,672 and $63,810 were made during the years ended December 31, 2014 and 2013, respectively, resulting in amounts due to the affiliate at December 31, 2014 and 2013 are approximately $270,747 and $237,480, respectively.

During June 2012, the Company borrowed $125,000 from an affiliate.  The loan bears interest at 10% per annum and is unsecured and payable upon demand. The Company has paid $0 toward the loan amount during 2014. The outstanding balance as of December 31, 2014 is $77,401 and accrued interest of $23,845.

On August 28, 2014, the Company authorized the purchase of 64,666,619 shares of common stock from affiliate at $0.001 per share and signed an unsecured promissory note for a total of $64,667 to affect the purchase. The loan bears interest at 6% per annum and is unsecured and payable upon demand.  The Company has paid $0 towards the loan amount during 2014.  The outstanding balance as of December 31, 2014 is $64,667. During 2014, the Company accrued the interest $1,329.

On August 28, 2014, the Company authorized the purchase of 3,000,000 shares of common stock from shareholder at $0.005 per share and signed a promissory note for a total of $15,000 to affect the purchase. The loan bears interest at 6% per annum and is unsecured and payable upon demand.  The Company has paid $0 towards the loan amount during 2014.  The outstanding balance as of December 31, 2014 is $15,000. During 2014, the Company accrued the interest $308.

The Company periodically rents a recreational vehicle from an affiliate of the Company, an entity owned by the Company’s president, which is utilized for advertising and promotional events.  The Company is charged $1,729 for each month of use and is payable in arrears.  For the years ended December 31, 2014 and 2013, the Company recorded expense of approximately $3,237 and $1,052, respectively.

Other than the foregoing, none of the directors or executive officers of the Company, nor any person who owned of record or was known to own beneficially more than 5% of the Company’s outstanding shares of its Common Stock, nor any associate or affiliate of such persons or companies, has any material interest, direct or indirect, in any transaction that has occurred during the past fiscal year, or in any proposed transaction, which has materially affected or will affect the Company.

With regard to any future related party transaction, we plan to fully disclose any and all related party transactions in the following manner:

·

Disclosing such transactions in reports where required;

·

Disclosing in any and all filings with the SEC, where required;

·

Obtaining disinterested directors consent; and

·

Obtaining shareholder consent where required.

Director Independence

For purposes of determining director independence, we have applied the definitions set out in NASDAQ Rule 5605(a)(2). The OTCBB on which shares of Common Stock are quoted does not have any director independence requirements. The NASDAQ definition of “Independent Officer” means a person other than an Executive Officer or employee of the Company or any other individual having a relationship which, in the opinion

34

of the Company's Board of Directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

According to the NASDAQ definition, Charles J. Scimeca is not an independent director because he is also an executive officer of the Company.

Review, Approval or Ratification of Transactions with Related Persons

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 14.  PRINCIPAL ACCOUNTING FEES AND SERVICES.

		Year Ended December 31, 2014		Year Ended December 31, 2013
Audit fees	$	25,500	$	23,000
Audit-related fees	$	-	$	0
Tax fees	$	-	$	0
All other fees	$	-	$	0
Total	$	25,500	$	23,000

Audit Fees

During the fiscal years ended December 31, 2014, we incurred approximately $25,500 in fees to our principal independent accountants for professional services rendered in connection with the audit and reviews of our financial statements for fiscal years ended December 31, 2014.

During the fiscal year ended December 31, 2013, we incurred approximately $23,000 in fees to our principal independent accountants for professional services rendered in connection with the audit and reviews of our financial statements for fiscal year ended December 31, 2013.

Audit-Related Fees

The aggregate fees billed during the fiscal years ended December 31, 2014 and 2013 for assurance and related services by our principal independent accountants that are reasonably related to the performance of the audit or review of our financial statements (and are not reported under Item 9(e)(1) of Schedule 14A was $0 and $0, respectively.

Tax Fees

The aggregate fees billed during the fiscal years ended December 31, 2014 and 2013 for professional services rendered by our principal accountant tax compliance, tax advice and tax planning were $0 and $0, respectively.

All Other Fees

The aggregate fees billed during the fiscal years ended December 31, 2014 and 2013 for products and services provided by our principal independent accountants (other than the services reported in Items 9(e)(1) through 9(e)(3) of Schedule 14A was $0 and $0, respectively.

35

PART IV

ITEM 15.  EXHIBITS.

(a) Exhibits

Exhibit
Number	Description of Exhibit		Filing
3.1	Articles of Incorporation	Filed with the SEC on January 19, 2010 as part of the Company’s Registration of Securities on Form 10-12G.
3.1(a)	Restated Articles of Incorporation	Filed with the SEC on April 18, 2011 as part of the Company’s Current Report on Form 8-K.
3.2	Bylaws	Filed with the SEC on January 19, 2010 as part of the Company’s Registration of Securities on Form 10-12G.
3.2(a)	Amended Bylaws	Filed with the SEC on April 18, 2011 as part of the Company’s Current Report on Form 8-K.
10.1	Promissory Note between the Company and Joe-Val, Inc., dated March 27, 2012.	Filed with the SEC on March 27, 2012 as part of the Company’s Current Report on Form 8-K.
10.2	Promissory Note between the Company and Coast To Coast Equity Group, Inc., dated June 25, 2012.	Filed with the SEC on August 20, 2012 as part of the Company’s Quarterly Report on Form 10-Q.
10.3	Convertible debenture between the Company and Shane Case, dated September 26, 2012.	Filed with the SEC on November 19, 2012 as part of the Company’s Quarterly Report on Form 10-Q.
10.4	Distribution Agreement between Regenetech, Inc. and Renuéll Int’l, Inc., dated December 29, 2011 and Amended on December 13, 2012.	Filed with the SEC on January 17, 2013 as part of the Company’s S-1/A...
10.5	Form of Subscription Agreement.	Filed with the SEC on November 29, 2012 as part of the Company’s S-1/A.
10.6	Consulting Agreement between the Company and John Stickler.	Filed with the SEC on December, 27, 2012 as part of the Company’s S-1/A
10.7	Co-License Agreement by and between Technology Applications International Corporation and the National Aeronautics and Space Administration, dated September 30, 2013.	Filed with the SEC on October 4, 2013, as part of our Current Report on Form 8-K.
10.8	License Agreement by and between the Company and the National Aeronautics and Space Administration, dated July 25, 2014.	Filed with the SEC on August 14, 2014, as part of our Quarterly Report on Form 10-Q.
10.9	Form of Unsecured Promissory Note.	Filed with the SEC on August 28, 2014, as part of our Current Report on Form 8-K.
10.10	Distribution Agreement by and between the Company and Meditem Cyprus, Ltd., dated October 13, 2014.	Filed with the SEC on November 14, 2014, as part of our Quarterly Report on Form 10-Q.
10.11	Distribution Agreement by and between the Company and Yontem Cosmetics Dis Tic. Ltd. Sti, dated February 26, 2015	Filed with the SEC on April 15, 2015 as part of the Company’s Annual Report on Form 10-K.
16.1	Letter from Lake of Associates CPA’s LLC, dated March 12, 2013.	Filed with the SEC on March 14, 2013 as part of the Company’s Current Report on Form 8-K.
21.1	List of Subsidiaries	Filed with the SEC on April 16, 2012 as part of the Company’s Annual Report on Form 10-K.
31.1	Certification of Principal Executive Officer Pursuant to Rule 13a-14	Filed herewith.
31.2	Certification of Principal Financial Officer Pursuant to Rule 13a-14	Filed herewith.
32.1	Certification of CEO and CFO Pursuant to Section 906 of the Sarbanes-Oxley Act	Filed herewith.
101.INS*	XBRL Instance Document	Filed herewith.
101.SCH*	XBRL Taxonomy Extension Schema Document	Filed herewith.
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document	Filed herewith.
101.LAB*	XBRL Taxonomy Extension Labels Linkbase Document	Filed herewith.
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document	Filed herewith.
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document	Filed herewith.
*Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

36

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TECHNOLOGY APPLICATIONS INTERNATIONAL CORPORATION

Dated: June 2, 2015

/s/ Charles J. Scimeca

By: Charles J. Scimeca

Its: President, Principal Executive Officer & Principal Financial Officer (Principal Accounting Officer)

Pursuant to the requirement of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated:

Dated: June 2, 2015

/s/ Charles J. Scimeca

Charles J. Scimeca – Director

Dated: June 2, 2015

/s/ John Stickler

John Stickler – Director

37

EX-31.1

EXHIBIT 31.1   

EX-31.2

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14

I, Charles J. Scimeca, certify that:

1. I have reviewed this amended Annual Report on Form 10-K/A of Technology Applications International Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June 2, 2015

/s/ Charles J. Scimeca

By: Charles J. Scimeca

Its: Principal Financial Officer

EX-32.1

EXHIBIT 32.1   

XML

8. License Agreement - Derivative Liability Fair Value Adjustment (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Notes to Financial Statements
Derivative liability	$ 48,851	$ 349,940
Fair value adjustment	700,279	64,232
Adjustment due to conversion	(141,294)
Adjustment due to exercise warrant	(18,700)
New warrant issued with stock	$ 559,184

XML

x. Commitment (Details) (USD $)	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitment Payment Due	$ 3,297	$ 36,258	$ 39,555

XML

12. Significant Agreement (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014
Co-License Agreement on Patent
Royalty percent paid to NASA per the patent license	3.00%
Minimum royalty due to NASA per calendar year accounting period	$ 15,000
Total royalty due per calendar year accounting period	$ 15,000
Months to achieve practical application of patent required by license	18 months

XML

5. Machinery and Equipment (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 5,614	$ 4,091

XML

8. Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2014

Notes to Financial Statements

Derivative Liabilities

	Level 1	Level 2	Level 3	Fair Value at December 31, 2014
Liabilities
Derivative liability	-	$ 48,851	-	$                  48,851

	Level 1	Level 2	Level 3	Fair Value at December 31, 2013
Liabilities
Derivative liability	-	$ 349,940	-	$                  349,940

Derivative Liability Fair Value Adjustment

Balance at December 31, 2013	349,940
Adjustment due to conversions	(141,294)
Adjustment due to exercise warrant	(18,700)
New warrant issued with stock	559,184
Fair value adjustment	(700,279)
Balance at December 31, 2014	$ 48,851

XML

9. Derivative Financial Instruments (Details Narrative)	Dec. 31, 2014
Notes to Financial Statements
Derivative financial instruments are indexed to an aggregate amount of shares	189,963

XML

7. Common Stock (Details Narrative) (USD $)	1 Months Ended				3 Months Ended		12 Months Ended		24 Months Ended
	Apr. 30, 2014	Mar. 31, 2014	Feb. 28, 2014	Dec. 31, 2013 Units	Sep. 30, 2014	Apr. 30, 2014	Dec. 31, 2014	Dec. 31, 2013 Units	Dec. 31, 2012	Mar. 14, 2015	Mar. 10, 2015	Mar. 06, 2015	Feb. 23, 2015	Feb. 21, 2015	Feb. 19, 2015	Feb. 18, 2015	Feb. 03, 2015	Feb. 02, 2015	Jan. 27, 2015	Dec. 28, 2014	Aug. 28, 2014	Aug. 22, 2014	Jul. 31, 2014	Jul. 07, 2014	Apr. 16, 2014	Apr. 03, 2014	Sep. 25, 2013	Aug. 14, 2013	Jul. 29, 2013	Jun. 10, 2013	May 31, 2013	May 23, 2013	Apr. 03, 2013	Feb. 13, 2013 Units	Sep. 25, 2012	Mar. 22, 2012
Notes to Financial Statements
Common stock issued for cash, shares											52,000		10,000	14,000		50,000	216,000	12,000	10,000	20,000		99,963	20,000	50,000	20,000	5,000
Common stock issued for cash, value																						$ 99,963	$ 20,000	$ 50,000	$ 10,000	$ 5,000
Common stock issued for cash, shares, duration		601,000
Common stock issued for cash, value, duration		300,500					201,435
Common stock issued for services, shares										110,000		15,000			25,000	15,000
Private placement units offered																																		3,000,000
Shares per unit																																		1
Common stock price per share											$ 0.50		$ 0.50	$ 0.50		$ 0.50	$ 0.50		$ 0.50	$ 0.50		$ 1.00	$ 1.00	$ 1.00	$ 0.50	$ 1.00								$ 1.00
Warrants per unit																																		1
Class A Warrants, shares per warrant																																		1
Exercise price per share in warrant																				$ 2.00														$ 1.50
Expiration of warrants, years								1 year
Expiration of warrants, days after common stock is quoted on OTCBB								180 days
Number of untis sold in February 13, 2013 private offering				0				0
Number of warrant shares issued, shares		601,000							1,030,000
Common stock issued for debt, shares, duration	41,534		565,615	100,000		607,119
Common stock issued for debt, amount, duration	20,000		254,000	50,000		304,049
Common stock issued for debt, price per share	$ 0.50		$ 0.50	$ 0.50		$ 0.50
Common stock issued for accrued interest on debt, amount, duration	1,534		29,282
Common stock issued for cash, price per share		$ 0.50
Warrants issued for debenture conversion		485,000		100,000		607,119
Exercise price of warrants issued for debenture conversion		$ 1.00		$ 1.00		$ 1.00
Subscription receivable		66,500
Exercise price of warrants issued for stock purchase, duration		$ 1.00			$ 2.00
Warrant expiration period	180 days				1 year		1 year
Valuation of warrants issued					525,623		561,281
Warrants included in stock issuance											52,000		10,000	14,000		50,000		12,000	10,000	20,000		99,963	20,000	50,000	20,000	5,000
Shares underlying warrants in stock issuance											52,000		10,000	14,000		50,000		12,000	10,000	20,000		99,963	20,000	50,000	20,000	5,000
Exercise price of warrants in stock issuance											$ 1.00		$ 1.00	$ 1.00		$ 1.00		$ 1.00	$ 1.00		$ 1.00				$ 1.00	$ 2.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00		$ 1.00	$ 1.00
Warrants issued for March/April 2014 debenture			226,515
Exercise price of warrants issued for March/April 2014 debenture			$ 1.00
Amount of debt converted from debentures							$ 254,000
Shares of common stock issued from conversion of debentures							485,000
Shares repurchased from shareholders and returned to treasury					68,666,619
Warrants exercised																					34,000
Exercise price of warrants exercised											$ 1.00		$ 1.00	$ 1.00		$ 1.00		$ 1.00	$ 1.00		$ 1.00				$ 1.00	$ 2.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00		$ 1.00	$ 1.00
Shares issued from exercise of warrants																					34,000

XML

13. Subsequent Events (Details Narrative) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended
	Feb. 26, 2015	Feb. 28, 2014	Dec. 31, 2014	Mar. 14, 2015	Mar. 10, 2015	Mar. 06, 2015	Feb. 23, 2015	Feb. 21, 2015	Feb. 19, 2015	Feb. 18, 2015	Feb. 03, 2015	Feb. 02, 2015	Jan. 27, 2015	Dec. 28, 2014	Aug. 28, 2014	Aug. 22, 2014	Jul. 31, 2014	Jul. 07, 2014	Apr. 16, 2014	Apr. 03, 2014	Sep. 25, 2013	Aug. 14, 2013	Jul. 29, 2013	Jun. 10, 2013	May 31, 2013	May 23, 2013	Apr. 03, 2013	Feb. 13, 2013	Sep. 25, 2012	Mar. 22, 2012
Subsequent Events [Abstract]
Common stock issued for cash, shares					52,000		10,000	14,000		50,000	216,000	12,000	10,000	20,000		99,963	20,000	50,000	20,000	5,000
Common stock issued for cash, value																$ 99,963	$ 20,000	$ 50,000	$ 10,000	$ 5,000
Common stock issued for cash, price per share					$ 0.50		$ 0.50	$ 0.50		$ 0.50	$ 0.50		$ 0.50	$ 0.50		$ 1.00	$ 1.00	$ 1.00	$ 0.50	$ 1.00								$ 1.00
Warrants included in stock issuance					52,000		10,000	14,000		50,000		12,000	10,000	20,000		99,963	20,000	50,000	20,000	5,000
Shares underlying warrants in stock issuance					52,000		10,000	14,000		50,000		12,000	10,000	20,000		99,963	20,000	50,000	20,000	5,000
Exercise price of warrants in stock issuance					$ 1.00		$ 1.00	$ 1.00		$ 1.00		$ 1.00	$ 1.00		$ 1.00				$ 1.00	$ 2.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00		$ 1.00	$ 1.00
Common stock issued for services, shares				110,000		15,000			25,000	15,000
Distribution agreement with Yontem
Skin cream units agreed to sell per month, first year minimum	1,000
Skin cream units agreed to sell per month, second year minimum	2,000
Skin cream units agreed to sell per month, third year minimum	3,000
Distibution Agreement duration	3 years
Warrants issued for March/April 2014 debenture		226,515
Exercise price of warrants issued for March/April 2014 debenture		$ 1.00
Amount of debt converted from debentures			$ 254,000
Shares of common stock issued from conversion of debentures			485,000

XML

3. Commitments and Contingencies

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

3. Commitments and Contingencies

3. Commitments and Contingencies

The Company leases its corporate office space under a month to month lease.

On September 10, 2014, the Company signed the office lease agreement. Commencement date is October 1, 2014 and lease term is 26 months. Monthly rental fee is $3,297 plus tax. The rent for October and November 2014 are free. Security deposit is $3,297 plus tax, which is $3,537. The first month for December 2014 and the last month rent are paid in 2014 amounting $7,056. Rental payment will be $42,333 in 2015 and $38,806 in 2016.

Rent expense was approximately $16,034 and $4,194 for the years ended December 31, 2014 and 2013, respectively.

During August 2012, the Company entered into a two-year commission agreement whereby it will pay a $35 commission for each product sold. The agreement will automatically renew in one-year increments unless cancelled in writing sixty-days prior to expiration.

As of December 31, 2014 and through the date of these financial statements, the Company has no insurance policies in place. As of the date of these financial statements, the Company has not been advised of any liability or claims against it.

XML

10. Income Tax Provision (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Income tax expense at statutory rate	$ 119,974	$ (243,286)
Change in derivative liability	(238,095)	21,839
Common stock issued for services rendered	0	0
Interest on derivative	90,866	77,398
Valuation allowance	267,203	187,726
Income tax expense per books	$ 0	$ 0

XML

2. Major Customers (Details Narrative)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Notes to Financial Statements
Major Customers	2	2
Total sales from major customers	74.00%	70.00%

XML

1. Nature of Operations and Basis of Presentation (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2020	Jan. 01, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Notes to Financial Statements
Amortization expense related to trademarks	$ 1,082	$ 109
Estimated future amortization expense related to trademarks	2,252		2,252	4,599	2,252	2,252	2,252	2,252	2,252
Research and development costs	6,653	8,319
Advertising and marketing costs	102,886	86,442
Derivative liabilities	48,851	349,940
FDIC insured value		250,000
Oustanding warrants	189,963	100,000
Impaired assets	0
Interest expense	$ 0	$ 0

XML

10. Income Taxes (Details Narrative)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Federal and state income tax rate	34.00%	34.00%
NOL carry-forwards expire through year	2033	2033

XML

3. Commitments and Contingencies (Details Narrative) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended
	Sep. 11, 2014	Aug. 31, 2012	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Rental Lease commitment	26 months				26 months
Monthly office rental fee					$ 3,297
Security Deposit on office rental					3,537
Rent expense					16,034	4,194
Future rent expense			38,806	42,333
Commission agreement amount per product sold		$ 35
Period of commission agreement		2 years
Automatic commission agreement renewal increments		1 year
Advance cancellation notice required on commission agreement expiration		60 days

XML

4. Inventories (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Inventory Disclosure [Abstract]
Raw materials	$ 0	$ 0
Work-in-process	0	0
Finished goods	4,831	70,862
Total Inventories	$ 4,831	$ 70,862

XML

2. Major Customers

3 Months Ended

Dec. 31, 2014

Notes to Financial Statements

2. Major Customers

2. Major Customers

Two customers accounted for approximately 74% and 70% of total sales for the years ended December 31, 2014 and 2013, respectively.

XML

5. Machinery and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014
Computer Equipment	4,162	$ 5,980
Machinery and equipment	13,418	29,935
Furniture and fixtures	14,073	14,073
Accumulated depreciation	(12,282)	(17,896)
Machinery and equipment, net	19,371	$ 32,092
Computer Equipment
Estimated useful lives, min	3 years
Machinery and Equipment
Estimated useful lives, min	5 years
Estimated useful lives, max	7 years
Furniture and Fixtures
Estimated useful lives, min	7 years

XML

8. License Agreement (Details Narrative) (USD $)	3 Months Ended
	Sep. 30, 2014	Jul. 25, 2014 Products Patents
Notes to Financial Statements
Royalty percent paid to NASA for use of two patent in exclusive License Agreement		3.00%
Number of patents included in exclusive License Agreement with NASA		2
Non-refundable license fee paid to NASA upon execution of License Agreement		$ 15,000
Second License Agreement fee due to NASA		15,000
Due date of second license fee due to NASA	6 months
Minimum annual royalty due to NASA for License Agreement		$ 15,000
Required time period to reach practical application of patents with License Agreement	18 months
Required number of products required to be filled, packaged, and have distribution by December 2014		5

XML

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets
Cash and cash equivalents	$ 39,501	$ 4,891
Inventories	4,831	70,862
Deposits	7,000	7,000
Other current assets	1,722	1,909
Total current assets	53,053	84,662
Intangible assets, net	15,859	1,940
Machinery and equipment, net	32,092	19,371
Other Assets
Security deposits	3,725	0
Total assets	104,728	105,973
Liabilities
Accounts payable and accrued expenses	458,783	344,415
Advances from affiliate	270,747	237,480
Loan from affiliate	157,068	77,401
Convertible debentures (net of debt discount of $0 and $75,902 respectively)	0	198,099
Deferred rent	2,713	0
Derivative liability	48,851	349,940
Total current liabilities	938,162	1,207,335
Total liabilities	938,162	1,207,335
Shareholders' deficit
Preferred stock, par value, $0.001 per share, 50,000,000 shares authorized, none issued or outstanding	0	0
Common stock, par value $0.001 par value, 300,000,000 shares authorized, 50,138,493 and 117,348,000 shares issued and outstanding at December 31, 2014 and December 31, 2013, respectively.	50,138	117,348
Additional paid in capital	1,274,202	586,199
Accumulated deficit	(2,157,774)	(1,804,909)
Total shareholders' deficit	(833,434)	(1,101,362)
Total liabilities and shareholders' deficit	$ 104,728	$ 105,973

XML

11. Related Parties (Details Narrative) (USD $)	1 Months Ended	12 Months Ended
	Jun. 30, 2012	Dec. 31, 2014	Dec. 31, 2013
Related Party Transactions [Abstract]
Affiliate advances		$ 152,938	$ 131,968
Payments made on affiliate advances		119,672	63,810
Due to affiliates		270,747	237,480
Loan from affiliate	125,000
Interest rate on loan from affiliate	10.00%
Repayments on loan from affiliate	0		11,479
Oustanding balance on loan from affiliate		77,401
Periodic monthly rental fee for President's recreational vehicle			1,052
Monthly rent cost for President's recreational vehicle		1,729	1,729
Recorded expense		3,237	1,052
Accrued interest	$ 23,845		$ 8,225

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities
Net loss	$ (352,865)	$ (715,546)
Adjustments to reconcile net income to net cash used in operating activities:
Gain on derivative valuation	(700,279)	(64,232)
Derivative expense	267,253	0
Gain on forgiveness of debts	0	(1,000)
Amortization of discount on convertible debentures	75,901	182,197
Depreciation and amortization	6,695	4,200
Shares issued for services rendered	0	0
Change in current assets and current liabilities:
Inventory	66,031	54,546
Deposits	0
Other current assets	(3,536)	1,905
Accounts payable and accrued expenses	144,302	150,521
Other current liabilities	2,713	0
Net cash used in operating activities	(493,785)	(297,964)
Cash flows from investing activities
Purchase of equipment	(18,335)	(10,000)
Payment in intangible assets	(15,000)	0
Net cash used in investing activities	(33,335)	(10,000)
Cash flows from financing activities
Advances from (to) affiliate, net	152,939	131,968
Repayment of loan from affiliate	(119,672)	(63,810)
Proceeds from issuance of convertible debenture	0	124,000
Payment of common stock purchase back	(1,000)	0
Proceeds from issuance of common stock	529,463	0
Net cash provided by financing activities	561,730	192,158
Net change in cash and cash equivalents	34,610	(115,806)
Cash and cash equivalents, beginning balance	4,891	120,697
Cash and cash equivalents, ending balance	39,501	4,891
Supplemental disclosure of cash flow information
Income taxes paid	0	0
Interest paid	0	0
Non-cash transactions
Issued notes payable for common stock buyback	79,667	0
Issuance of common stock for convertible notes converted	447,325	0
Subscription receivable	$ 52,700	$ 0

XML

6. Convertible Debenture (Details Narrative) (USD $)	1 Months Ended				12 Months Ended
	Apr. 30, 2014	Feb. 28, 2014	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2014	Dec. 31, 2013	Mar. 10, 2015	Feb. 23, 2015	Feb. 21, 2015	Feb. 18, 2015	Feb. 02, 2015	Jan. 27, 2015	Aug. 28, 2014	Apr. 16, 2014	Apr. 03, 2014	Sep. 25, 2013	Aug. 14, 2013	Jul. 29, 2013	Jun. 10, 2013	May 31, 2013	May 23, 2013	Apr. 03, 2013	Sep. 25, 2012	Mar. 22, 2012
Notes to Financial Statements
Deposit on distribution agreeement				$ 100,000
Deposit converted into convertible debenture																								100,000
Convertible debenture issued																20,000	50,000	4,000	25,000	10,000	10,000	5,000	100,000
Interest rate of convertible debenture, per annum																10.00%	10.00%	10.00%	10.00%	10.00%	10.00%	0.00%	5.00%	5.00%
Maturity date of convertible debenture						1 year
Debt conversion to common stock rate																$ 0.50	$ 0.50	$ 0.50	$ 0.50	$ 0.50	$ 0.50	$ 0.50	$ 0.50	$ 0.50
Number of warrants offered per share issued from converted debt																1	1	1	1	1	1	1	1	1
Warrants exercisable for common stock, price per share							$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 2.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00	$ 1.00
Expiration of warrants, years						1 year
Expiration of warrants, days after common stock is quoted on OTCBB						180 days
Initial Interest expense					267,253
Amortization expense					75,901	182,197
Gain (loss) on derivative valuation					700,279	64,232
Amount of debt converted from debentures					254,000
Shares of common stock issued from conversion of debentures					485,000
Amount of convertible debentures still outstanding					19,999
Debt discount on convertible debt					9,611
Net convertible debt					10,388
Amount of debt converted from 2013 debentures	20,767	110,866
Shares of common stock issued from conversion of 2013 debentures	41,543	220,785
Price per share of common stock converted from 2013 debentures		$ 0.50
Warrants issued for 2013 debentures	41,534	220,785
Exercise price of warrants issued for 2013 debentures	$ 1.00	$ 1.00
Expiration period of warrants issued for 2013 debentures		Sep. 21, 2014
Warrants outstanding of the 2013 debenture warrants					0
Amount of 2013 convertible debentures still outstanding					21,025
Amount of debt converted from December 2011 debenture		84,143	25,000
Shares of common stock issued from conversion of December 2011 debenture		168,285	50,000
Price per share of common stock converted from December 2011 debenture			$ 0.50
Amount of debt converted from September 2012 debenture		88,273	25,000
Shares of common stock issued from conversion of September 2012 debenture		176,515	50,000
Price per share of common stock converted from September 2012 debenture		$ 0.50	$ 0.50
Warrants issued for December 2011 debenture		218,285
Exercise price of warrants issued for December 2011 debenture		$ 1.00
Expiration date of warrants issued for December 2011 debenture		Sep. 21, 2014
Warrants outstanding of the December 2011 debenture warrants					0
Warrants issued for September 2012 debenture		226,515
Exercise price of warrants issued for September 2012 debenture		$ 1.00
Expiration date of warrants issued for September 2012 debenture		Sep. 21, 2014
Warrants outstanding of the September 2012 debenture warrants					0
Unsecured promissory note due RAJ Ventures													$ 15,000
Interest rate of promissory note due RAJ Ventures													6.00%

XML

4. Inventories (Tables)

12 Months Ended

Dec. 31, 2014

Inventory Disclosure [Abstract]

Inventories

	December 31,
		2014		2013
Raw materials	$	-	$	-
Work-in-process		-		-
Finished goods		4,831		70,862
Total Inventories, net	$	4,831	$	70,862

XML

7. Common Stock (Details) (USD $)	1 Months Ended	24 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013
Number of Warrant Shares, duration	601,000	1,030,000
Exercisable
Number of Warrant Shares, instant			189,963	100,000
Weighted Average Exercise Price, instant			$ 1.60	$ 1.00
Intrinsic Value, instant			$ 0
Outstanding
Number of Warrant Shares, instant				100,000
Weighted Average Exercise Price, instant				$ 1.00
Expired
Number of Warrant Shares, duration			(1,299,149)
Weighted Average Exercise Price, duration			$ 1.04
Remaining term, duration			9 months
Intrinsic Value, duration			$ 0
Exercised
Number of Warrant Shares, duration			(34,000)
Granted
Number of Warrant Shares, duration			1,403,112
Weighted Average Exercise Price, duration			$ 1.12

XML

7. Common Stock (Tables)

12 Months Ended

Dec. 31, 2014

Notes to Financial Statements

Warrant Activity

	Shares	Weighted-Average Exercise Price Per Share	Remaining term	Intrinsic value
Outstanding, December 31, 2013	100,000	1.00
Exercisable at December 31, 2013	100,000	1.00
Granted	1,423,112	1.16
Exercised	(34,000)	1.00
Expired	(1,299,149)	1.04	0.79 year	$ 0
Exercisable at December 31, 2014	189,963	2.00	0.79 year	$ 0

XML

1. Nature of Operations and Basis of Presentation

12 Months Ended

Dec. 31, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

1. Nature of Operations and Basis of Presentation

1. Nature of Operations and Basis of Presentation

Nature of Operations

Technology Applications International Corporation (“Technology”) was incorporated on October 14, 2009 under the laws of Florida. Rejuvel Int’l, Inc. and NueEarth, Inc., Technology’s wholly owned subsidiaries and Technology, collectively, are referred to here-in as the “Company”. The Company is engaged in developing market entry technology products and services into early and mainstream technology products and services. Through our subsidiaries, we are focused on developing and manufacturing a line of technologically advanced skin care products and providing environmental management solutions that use electron particle accelerator technology.

Principles of Consolidation

The consolidated financial statements include the accounts of Technology Applications International Corporation and its wholly owned subsidiaries, Rejuvel Int’l, Inc. and NueEarth, Inc. All significant inter-company accounts and transactions have been eliminated in consolidation.

Basis of Presentation and Going Concern Considerations

The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) applicable to a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Realization values may be substantially different from carrying values as shown and these financial statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs. The Company’s ability to continue as a going concern is highly dependent upon management’s ability to increase near-term operating cash flows and obtain additional working capital through the issuance of debt and or equity.

Management intends to finance operating costs over the next twelve months with existing cash on hand, from the issuance of common shares, and additional related party borrowings. The Company's future operations are dependent upon external funding and its ability to execute its business plan, realize sales and control expenses. Management believes that sufficient funding will be available from additional borrowings and private placements to meet its business objectives including anticipated cash needs for working capital, for a reasonable period of time. However, there can be no assurance that the Company will be able to obtain sufficient funds to continue the development of its business operation, or if obtained, upon terms favorable to the Company. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

Development Stage Risk

Since its inception, the Company has been dependent upon the receipt of capital investment to fund its operating activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plans will be successfully executed. The Company’s ability to execute its business plans is dependent on its ability to obtain additional debt and equity financing and achieving a profitable level of operations. There can be no assurance that sufficient financing will be obtained or that we will achieve a profitable level of operations.

 Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and their reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Risks and Uncertainties

The Company is subject to substantial risks from, among other things, intense competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements and limited operating history.

Contingencies

Certain conditions may exist as of the date the consolidated financial statements are issued which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company's management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company's legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be provided for in the Company's consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.

There were no contingencies which could be evaluated at December 31, 2014.

Cash and Cash Equivalents

Cash and cash equivalents consist of highly-liquid investments with a maturity of less than three months when purchased.

Inventories

Inventories are stated at the lower of cost or market value using the FIFO (first-in, first-out) method.

The Company maintains a reserve for the inventory based on the estimated losses that result from inventory that becomes obsolete or for which the Company has excess inventory levels as of period end. In determining these estimates, the Company performs an analysis on current demand and usage for each inventory item over historical time periods. Based on that analysis, the Company reserves a percentage of the inventory amount within each time period based on historical demand and usage patterns of specific items in inventory.

Machinery and Equipment

Machinery and equipment are recorded at cost. Expenditures for maintenance and repairs are charged to earnings as incurred whereas additions, renewals and betterments are capitalized. When machinery and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of machinery and equipment is provided using the straight-line method over the assets estimated useful lives of approximately 5 to 7 years. Leasehold improvements, if any, are amortized on a straight-line basis over the term of the lease or the estimated useful lives, whichever is shorter.

Intangible Assets

Intangible consist of trademarks and licenses (Trademarks have a 20 year life and licenses have a 7 year life.) which are being amortized using the straight-line method over their estimated period of benefit. We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. All of our intangible assets are subject to amortization. No impairments of intangible assets have been identified during any of the periods presented.

2015	2,252
2016	2,252
2017	2,252
2018	2,252
2019	2,252
Thereafter	4,599

Amortization expense for the years ended December 31, 2014 and 2013 was $1,082 and $109, respectively.

Long-Lived Assets

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of definite-lived assets to be held and used is measured by comparison of the carrying amount of an asset to future undiscounted cash flow expected to be generated by the asset. If such assets are impaired, the impairment is recognized as the amount by which the carrying amount exceeds the estimated future cash flows. Assets to be sold are reported at the lower of the carrying amount or the fair value less costs to sell. Indefinite-lived assets are tested for impairment annually or when impairment is suspected by a comparison of the carrying amount of the asset to the net present value of future cash flows expected to be generated by the asset. There were no impaired assets at December 31, 2014.

Revenue Recognition

The Company's revenue recognition policies are in compliance with Staff Accounting Bulletin No. 104, "Revenue Recognition." Sales revenue which has been insignificant to December 31, 2014, is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue.

Research and Development Costs

Research and development costs, which relate primarily to the development, design and testing of products, are expensed as incurred. Such costs were approximately $6,563 and $8,319 for the years ended December 31, 2014 and 2013, respectively.

Advertising and Marketing

Advertising and marketing expenses are expensed as incurred. Expense recorded for the years ended December 31, 2014 and 2013 were approximately $102,886 and $86,442, respectively.

Fair Value of Financial Instruments

In accordance with FASB ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

In determining fair value, the Company uses various valuation approaches. In accordance with GAAP, a fair value hierarchy for inputs is used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the inputs market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels based on the inputs as follows:

· Level 1 — Inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.

· Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.

· Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

As of December 31, 2014 and December 31, 2013, the derivative liabilities amounted to $48,851 and $349,940, respectively. In accordance with the accounting standards, the Company determined that the carrying value of these derivatives approximated the fair value using the level 2 inputs.

Derivative Financial Instruments

Derivative financial instruments, as defined in Financial Accounting Standards, consist of financial instruments or other contracts that contain a notional amount and one or more underlying components (e.g. interest rate, security price or other variable), require no initial net investment and permit net settlement. Derivative financial instruments may be free-standing or embedded in other financial instruments. Further, derivative financial instruments are initially, and subsequently, measured at fair value and recorded as liabilities or, in rare instances, assets. The Company generally does not use derivative financial instruments to hedge exposures to cash-flow or market or foreign-currency risks. However, the Company has entered into various types of financing arrangements to fund its business capital requirements, including convertible debt and other financial instruments indexed to the Company’s own stock. These contracts require careful evaluation to determine whether derivative features embedded in host contracts require bifurcation and fair value measurement or, in the case of freestanding derivatives (principally warrants) whether certain conditions for equity classification have been achieved. In instances where derivative financial instruments require liability classification, the Company is required to initially, and subsequently, measure such instruments at fair value. Accordingly, the Company adjusts the fair value of these derivative components at each reporting period through a charge to income until such time as the instruments acquire classification in stockholders’ equity. See Note 8 for additional information.

As previously stated, derivative financial instruments are initially recorded at fair value and subsequently adjusted to fair value at the close of each reporting period. The Company estimates fair values of derivative financial instruments using various techniques (and combinations thereof) that are considered to be consistent with the objective measuring fair values. In selecting the appropriate technique, management considers, among other factors, the nature of the instrument, the market risks that it embodies and the expected means of settlement. For less complex derivative instruments, such as free-standing warrants, the Company uses the Black-Scholes-Merton option valuation technique because it embodies all of the requisite assumptions (including trading volatility, dividend yield, estimated terms and risk free rates) necessary to fair value these instruments. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are highly volatile and sensitive to changes in the trading market price of our common stock, which has a high-historical volatility. Since derivative financial instruments are initially, and subsequently, carried at fair values, our income (loss) will reflect the volatility in these estimate and assumption changes.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income during the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses. No interest expense or penalties have been assessed as of, and for the years ended, December 31, 2014 and 2013.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash accounts. The Company places its cash in what it believes to be credit-worthy financial institutions. Accounts at each financial institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At December 31, 2014 and 2013, the Company’s cash balances did not exceed federally insured limits.

Earnings (Loss) Per Common Share

The Company computes earnings per share in accordance with ASC 260, Earnings Per Share (“ASC 260”). Basic earnings (loss) per share are computed by dividing the net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted earnings per share adjusts basic earnings per share for the effects of stock options and other potentially dilutive financial instruments, only in the periods in which the effects are dilutive.

For the years ended December 31, 2014 and 2013, there were warrants to purchase 189,963 shares and 100,000 shares, respectively, of common stock that were excluded from the diluted earnings per share computation because the impact of the assumed exercise of such warrants would have been anti-dilutive, based on the fact that their exercise price exceeded the market price of the common stock as of December 31, 2014 and 2013.

Recent Accounting Pronouncements

On June 10, 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-10 (ASU 2014-10), Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. ASU 2014-10 eliminates the requirement to present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclosure the risks and uncertainties related to their activities. ASU 2014-10 also eliminates an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The presentation and disclosure requirements in Topic 915 will no longer be required for interim and annual reporting periods beginning after December 15, 2014, and the revised consolidation standards will take effect in annual periods beginning after December 15, 2015. Early adoption is permitted. The Company adopted the provisions of ASU 2014-10 effective for its financial statements for the interim period ended September 30, 2014. The adoption of ASU 2014-10 did not have any effect on the Company’s financial statement presentation or disclosures.

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position or results of operations upon adoption.

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	50,138,493	117,348,000
Common stock, shares outstanding	50,138,493	117,348,000
Discount on convertible debentures	$ 0	$ 75,902

XML

11. Related Parties

12 Months Ended

Dec. 31, 2014

Related Party Transactions [Abstract]

11. Related Parties

11. Related Parties

An affiliate of the Company, the Company’s president, has been funding operations of the Company by making payments directly to third parties or advancing monies to the Company. These amounts bear no interest and are payable on demand. Amounts advanced to the Company during the years ended December 31, 2014 and 2013 were approximately $152,938 and $131,968, respectively. Payments of approximately $119,672 and $63,810 were made during the years ended December 31, 2014 and 2013, respectively, resulting in amounts due to the affiliate at December 31, 2014 and 2013 are approximately $270,747 and $237,480, respectively.

During June 2012, the Company borrowed $125,000 from an affiliate. The loan bears interest at 10% per annum and is unsecured and payable upon demand. The Company has paid $0 toward the loan amount during 2014. The outstanding balance as of December 31, 2014 is $77,401 and accrued interest of $23,845.

On August 28, 2014, the Company authorized the purchase of 64,666,619 shares of common stock from affiliate at $0.001 per share and signed an unsecured promissory note for a total of $64,667 to affect the purchase. The loan bears interest at 6% per annum and is unsecured and payable upon demand. The Company has paid $0 towards the loan amount during 2014. The outstanding balance as of December 31, 2014 is $64,667. During 2014, the Company accrued the interest $1,329.

On August 28, 2014, the Company authorized the purchase of 3,000,000 shares of common stock from shareholder at $0.005 per share and signed a promissory note for a total of $15,000 to affect the purchase. The loan bears interest at 6% per annum and is unsecured and payable upon demand. The Company has paid $0 towards the loan amount during 2014. The outstanding balance as of December 31, 2014 is $15,000. During 2014, the Company accrued the interest $308.

The Company periodically rents a recreational vehicle from an affiliate of the Company, an entity owned by the Company’s president, which is utilized for advertising and promotional events. The Company is charged $1,729 for each month of use and is payable in arrears. For the years ended December 31, 2014 and 2013, the Company recorded expense of approximately $3,237 and $1,052, respectively.

XML

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Apr. 15, 2015	Jun. 30, 2014
Document And Entity Information
Entity Registrant Name	Technology Applications International Corp
Entity Central Index Key	0001481427
Document Type	10-K
Document Period End Date	Dec. 31, 2014
Amendment Flag	true
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 18,380,871
Entity Common Stock, Shares Outstanding		50,473,093
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014
Amendment Description	Amendment #2

XML

12. Significant Agreement

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

12. Significant Agreement

12. Significant Agreement

On September 30, 2013, the Company and its wholly-owned subsidiary Rejuvel Int’l, Inc., Florida corporations (the “Company”) entered into a partially exclusive Co-License Agreement (the “License Agreement”) by and amongst the National Aeronautics and Space Administration, an agency of the United States (“N.A.S.A.”) and the Administrators of the Tulane Educational Fund (“Tulane University”) for the use of U.S. Patent No. 6,730,498 B1, an invention entitled “Production of Functional Proteins: Balance of Shear Stress and Gravity,” which was issued on May 4, 2004 (the “Patent”). The company currently uses the Patent process to develop our anti-aging skin creams and shampoos. The License Agreement permits the Company to use the Patent as well as the name N.A.S.A., with its products, as per the terms of the License Agreement.

On July 25, 2014, Technology Applications International Corporation and its wholly-owned subsidiary Rejuvel Int’l, Inc., Florida corporations (the “Company”) entered into an exclusive License Agreement (the “License Agreement”) by and between the National Aeronautics and Space Administration, an agency of the United States (“N.A.S.A.”) for the use of U.S. Patent No.’s 6,485,963 B1, an invention entitled “Growth Stimulation Of Biological Cells and Tissue By Electromagnetic Fields and Uses Thereof” which was filed on June 2, 2000, and U.S. Patent No. 6,673,597 B2, for an invention entitled “Growth Stimulation of Biological Cells and Tissue By Electromagnetic Fields and Uses Thereof, which was filed on February 28, 2001 (the “Patents”). We currently use the Patents process to develop our anti-aging skin creams and shampoos. The License Agreement permits the Company to use the Patents as well as the name N.A.S.A., with its products, as per the terms of the License Agreement.

In consideration of the grant of the License Agreement, the Company will pay a 3% royalty to N.A.S.A. on the gross sales of any royalty-base products. The License agreement further requires the Company to remit to N.A.S.A. a non-refundable license fee in the amount of Fifteen Thousand Dollars ($15,000) upon the execution of the License Agreement and then another Fifteen Thousand Dollars ($15,000) is due six months after the license commencement date. The Company also agrees to pay N.A.S.A. a minimum royalty of Fifteen Thousand Dollars ($15,000), at the end of each accounting period (“Accounting Period”). The Accounting Period shall begin at the end of the second Accounting period of the License Agreement and each Accounting period thereafter.

The License Agreement requires that the Company achieve a practical application of the Patent within eighteen (18) months from the commencement date of the License Agreement. In accordance with the appendix to the License Agreement; wherein it states that by August 2014, the Company shall have tested the product to meet federal, state and international regulations of its skin cream products, by October 2014, the Company shall have packaged and filled five products and by December 2014, the Company shall have Domestic and International distribution of five products. Once a practical application is achieved the term of the agreement shall be equal to the unexpired term of the last patent to be in effect of the patent(s) encompassed under the Patents. The Company further agrees that any products using the Patents process shall be substantially manufactured in the United States. As of the Date of this filing all milestones associated with the License Agreement have been completed on time and to the satisfaction of the License Agreement Parties.

On October 4, 2013, the Company terminated its distribution agreement (“Distribution Agreement”) by and between the Company and Regenetech, Inc., a Texas corporation, pursuant to the termination clauses contained within the Distribution Agreement. Regenetech, Inc., was in a material breach of contract of the Distribution Agreement, because Regenetech, Inc., failed to upkeep its license requirements with N.A.S.A. and the Tulane University in order to maintain the license in good standing. Due to the material breach of contract by Regenetech, Inc., the termination of the Distribution Agreement does not contain any early termination penalties to the Company.

XML

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Revenues	$ 94,096	$ 51,559
Cost of revenues	83,304	26,805
Gross profit	10,792	24,754
Expenses
General and administrative	697,997	554,460
Loss From Operation	(68,705)	(529,706)
Other income (expense)
Gain on derivative valuation	700,279	64,232
Derivative expense	(267,253)	0
Gain on forgiveness of debts	0	1,000
Interest expense	(98,686)	(251,072)
Total other income (expense)	334,340	(185,840)
Net Income (Loss)	$ (352,865)	$ (715,546)
Loss per share
Basic and diluted	$ 0.00	$ (0.01)
Weighted average number of shares
Basic and diluted	94,507,750	117,248,274

XML

6. Convertible Debenture

12 Months Ended

Dec. 31, 2014

Notes to Financial Statements

6. Convertible Debenture

6. Convertible Debenture

During December 2011, the Company received $100,000 as a deposit for entering into a distribution agreement. On March 22, 2012, the Company converted the $100,000 deposit into a convertible debenture. The convertible debenture bears interest at a rate of five-percent (5%) per annum and was payable March 21, 2014. At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share. In addition to the common stock, the Holder received warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share. These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise. In December 2013, the Noteholder elected to convert $25,000 into 50,000 shares of the Company’s Common Stock at $0.50 per share. In February 2014, the Noteholder elected to convert $84,143 (including accrued interest of $9,143) into 168,285 shares of the Company’s Common Stock at $0.50 per share. The Company issued 218,285 warrants to purchase a 218,285 shares of common stock exercisable at $1.00 per share. As of December 31, 2014, 218,285 warrants are expired.

On September 25, 2012, the Company issued a $100,000 convertible debenture. The convertible debenture bears interest at a rate of five-percent (5%) per annum and was payable September 20, 2013. At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share. In addition to the common stock, the Holder received warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share. These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise. This convertible debenture extended 360 days on September 21, 2013. In December 2013, the Noteholder elected to convert $25,000 into 50,000 shares of the Company’s Common Stock at $0.50 per share. In February 2014, the Noteholder elected to convert $88,273 (including accrued interest of $13,273) into 176,515 shares of the Company’s Common Stock at $0.50 per share. The Company issued 226,515 warrants to purchase a 226,515 shares of common stock exercisable at $1.00 per share. As of December 31, 2014, 226,515 warrants are expired.

On April 3, May 23, May 31, June 10, July 29, August 14, and September 25, 2013 the Company issued $5,000, $10,000, $10,000, $25,000, $4,000, $50,000 and $20,000 convertible debentures, respectively. The convertible debentures bear interest at a rate of ten-percent (10%) per annum and is payable March 29, May 18, May 26, June 5, July 24, August 9, and September 20, 2014, respectively. At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share. In addition to the common stock, the Holder shall receive warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share. These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise. In February 2014, the Noteholder elected to convert $110,866 (including accrued interest of $6,866) into 220,785 shares of the Company’s Common Stock at $0.50 per share. The Company issued 220,785 warrants to purchase 220,785 shares of common stock exercisable at $1.00 per share. In April 2014, the Noteholder elected to convert $21,534 (including accrued interest of $1,534) into 41,534 shares of the Company’s Common Stock at $0.50 per share. The Company issued 41,534 warrants to purchase 41,534 shares of common stock exercisable at $1.00 per share. As of December 31, 2014, 262,319 warrants are expired.

The Compound derivative comprises certain derivative features embedded in the host convertible debenture contracts including the conversion feature and warrants both of which contain anti-dilution protections. These instruments were combined into one compound derivative and bifurcated from the host instrument at fair value. The Company applied the Black-Scholes Merton valuation technique to fair value these derivatives because this technique embodies all of the assumptions necessary to fair value these compound derivative instruments. Since the derivative financial instruments are required to be recorded, both initially, and subsequently, at fair value, there were insufficient proceeds to allocate any amount to the convertible debentures and, accordingly, it has no carrying value on the date of inception. Additionally, proceeds were insufficient to record the fair values of the derivative financial instruments, resulting in initial interest expense of $267,253. It should be noted that the derivative instruments will be adjusted to fair value at each reporting date. As the Company does not have historical volatility data for its own stock, the expected volatility was based upon the Company’s peer group in the industry in which it does business. Fair values are highly influenced by the trading stock price and volatility of the peer group, changes in our credit risk and market interest rates. The company amortizes the discount on the convertible debentures resulting from the initial allocation over the term of the convertible debt instruments using the effective method. Amortization expense arising from this method for the years ended December 31, 2014 and 2013 amounted to $75,901 and $182,197 which have been included as a component of interest expense. For the year ended December 31, 2014, gain on derivative valuation was $700,279 (For the year ended December 31, 2013, gain on the derivative valuation was $64,232)

XML

5. Machinery and Equipment

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

5. Machinery and Equipment

5. Machinery and Equipment

Machinery and equipment, as of December 31, 2014 and December 31, 2013, consisted of the following:

	Estimated Useful Lives	December 31, 2014	December 31, 2013
Computer Equipment	3 Years	$ 5,980	$ 4,162
Machinery and equipment	5 Years	29,935	13,418
Furniture and fixtures	7 Years	14,073	14,074
Accumulated depreciation		(17,896)	(12,283)
		$ 32,092	$ 19,371

Depreciation expense for the years ended December 31, 2014 and 2013 was $5,614 and $4,091, respectively.

XML

5. Machinery and Equipment (Tables)

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

Machinery and equipment

	Estimated Useful Lives	December 31, 2014	December 31, 2013
Computer Equipment	3 Years	$ 5,980	$ 4,162
Machinery and equipment	5 Years	29,935	13,418
Furniture and fixtures	7 Years	14,073	14,074
Accumulated depreciation		(17,896)	(12,283)
		$ 32,092	$ 19,371

XML

13. Subsequent Events

12 Months Ended

Dec. 31, 2014

Subsequent Events [Abstract]

13. Subsequent Events

13. Subsequent Events

On January 27, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of 1.00 per share. These warrants expire 360 days after stock issuance date.

On February 2, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.

On February 2, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.

On February 3, 2015, the Company entered stock subscription agreement for 21,600 shares at $0.50 per share.

On February 18, 2015, the Company entered stock subscription agreement of 50,000 shares at $0.50 per share with 50,000 warrants to purchase 50,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.

On February 18, 2015, the Company entered a consulting agreement whereby the Company issued 15,000 shares for consulting services, on a month to month basis.

On February 19, 2015, the Company entered a consulting agreement whereby the Company issued 25,000 shares for consulting services, on a month to month basis.

On February 21, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.

On February 21, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.

On February 21, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.

On February 23, 2015, the Company entered stock subscription agreement of 10,000 shares at $0.50 per share with 10,000 warrants to purchase 10,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.

On or about February 26, 2015, the Company entered into a distribution agreement (“Distribution Agreement”) with Yontem Cosmetics Dis Tic. Ltd. Sti (“Yontem”) a Turkish company; thereby, naming Turkey (the “Territory”) as an exclusive territory for Yontem. The terms of the Distribution Agreement, expects that Yontem will sell a minimum of 1,000 1.7oz units per month during the 1^st year, 2,000 1.7oz units per month during the second year of operation and 3,000 units per month in the third year upon the establishment of the company by Yontem. The Distribution Agreement is for an initial period of three years and then the two parties will evaluate the progress of the Distribution Agreement. The Distribution Agreement can then be renewed for an additional five-five year periods. The Distribution Agreement also states that in order to maintain exclusivity on the Territory the quota numbers must be met, and that if they are not met then Yontem will lose exclusivity to the Territory.

On March 6, 2015, the Company entered a service agreement whereby the Company issued 15,000 shares for marketing solution and strategy services, on a month to month basis.

On March 10, 2015, the Company entered stock subscription agreement of 50,000 shares at $0.50 per share with 50,000 warrants to purchase 50,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.

On March 10, 2015, the Company entered stock subscription agreement of 2,000 shares at $0.50 per share with 2,000 warrants to purchase 2,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 360 days after stock issuance date.

On March 14, 2015, the Company entered an independent contractor agreement whereby the Company issued 100,000 shares for medical services, for a period of one year.

On March 14, 2015, the Company entered an independent contractor agreement whereby the Company issued 10,000 shares for medical services, for a period of one year.

Pursuant to Accounting Standards Codification 855-10, the Company has evaluated all events or transactions that have occurred from December 31, 2014 through the filing with the SEC.

XML

9. Derivative Financial Instruments

12 Months Ended

Dec. 31, 2014

Investments, All Other Investments [Abstract]

9. Derivative Financial Instruments

9. Derivative Financial Instruments

The balance sheet caption derivative liability consists of derivative features embedded in convertible debentures including the conversion feature and warrants which have anti-dilution protections. These derivative financial instruments are indexed to an aggregate of 189,963 shares of the Company’s common stock as of December 31, 2014 and are carried at fair value. The balance at December 31, 2014 and 2013 was $48,851 and $349,940, respectively.

The valuation of the derivative liability is determined using a Black-Scholes Merton Model because that model embodies all of the relevant assumptions that address the features underlying these instruments. Significant assumptions used in the Black-Scholes models at December 31, 2014 include the following:

Risk-free interest rate	0.25%
Estimated volatility	186%
Dividend rate	None
Estimated term in years	0.5-1.1

XML

7. Common Stock

12 Months Ended

Dec. 31, 2014

Notes to Financial Statements

7. Capital Stock

7. Common Stock

In December 31, 2013, the Company issued 100,000 shares of its common stock at $0.50 for conversion of convertible debenture of $50,000. Also, the Company issued 100,000 warrants to purchase a 100,000 shares of common stock exercisable at $1.00 per share.

In February 2014, the Company issued 565,615 shares of its common stock at $0.50 for conversion of convertible debentures of $254,000 and 29,282 of accrued interest.

In March 2014, the Company issued 601,000 shares of its common stock at $0.50 through a private placement for total cash consideration of $300,500. Also, the Company issued 601,000 warrants to purchase to purchase 601,000 shares of common stock exercisable at $1.00 per share.

On April 3, 2014, the Company entered stock subscription agreement of 5,000 shares at $1.00 per share with 5,000 warrants to purchase 5,000 shares of common stock with an exercise price of $2.00 per share. These warrants expired 180 days after stock issuance date.

On April 8, 2014, the Company issued 41,534 shares of its common stock at $0.50 for conversion of a convertible debenture of $20,000 and $1,534 of accrued interest.

On April 16, 2014, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 20,000 warrants to purchase 20,000 shares of common stock with an exercise price of $1.00 per share. These warrants expired 180 days after stock issuance date.

On July 7, and July 31, 2014, the Company entered stock subscription agreements of 50,000 shares and 20,000 shares at $1.00 per share with 50,000 and 20,000 warrants to purchase 50,000 and 20,000 shares of common stock with an exercise price of $2.00 per share. These warrants expire 360 days after stock issuance date.

On August 22, 2014, the Company entered stock subscription agreement of 99,963 shares at $1.00 per share with 99,963 warrants to purchase 99,963 shares of common stock with an exercise price of $2.00 per share. These warrants expire 360 days after stock issuance date.

On August 28, 2014, the Company authorized the purchase of 64,666,619 shares of common stock from affiliate at $0.001 per share and signed a promissory note for a total of $64,667 to affect the purchase. The Company then cancelled the shares.

On August 28, 2014, the Company authorized the purchase of 3,000,000 shares of common stock from shareholder at $0.005 per share and signed a promissory note for a total of $15,000 to affect the purchase. The Company then cancelled the shares.

On September 9, 2014, a Warrant holder exercised 34,000 warrants to purchase 34,000 restricted common shares at a price of $1.00 per share.

On August 28, 2014, the Company authorized the purchase of 1,000,000 shares of common stock from shareholder at $0.001 per share and paid by cash $1,000 to affect the purchase. The Company then cancelled the shares.

On December 28, 2014, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 20,000 warrants to purchase 20,000 shares of common stock with an exercise price of $2.00 per share. These warrants expire 360 days after stock issuance date.

Due to a ratchet provision, the warrants issued during 2014 were accounted for as a derivative and fair valued using the Black Scholes valuation model. The initial valuation was $561,281.

Stock Purchase Warrants

In conjunction with the Private Placement Memorandum dated February 13, 2013, the Company is offering up to 3,000,000 units. Each unit consists of 1 share of common stock priced at $1.00 and one Class A Warrant to purchase 1 share of common stock with an exercise price of $1.50 per share. These warrants expire on the earlier of (i) 180 days after the common stock commences quotation on the OTC Bulletin Board or (ii) one year after the date of issuance. No issuances have been sold from this offering as of December 31, 2014.

In December 2013, Noteholders elected to convert $50,000 into 100,000 shares of the Company’s Common Stock at $0.50 per share. The Company issued 100,000 warrants to purchase 100,000 shares of common stock exercisable at $1.00 per share. The warrants were expired as of December 31, 2014.

In February and April 2014, the Noteholder elected to convert $304,816 (including accrued interest of $30,816) into 607,149 shares of the Company’s Common Stock at $0.50 per share. The Company issued 607,149 warrants to purchase a 607,149 shares of common stock exercisable at $1.00 per share. The warrants were expired as of December 31, 2014.

In March 2014, the Company issued 601,000 shares of its common stock at $0.50 through a private placement for total cash consideration of $300,500. Also, the Company issued 601,000 warrants to purchase 601,000 shares of common stock exercisable at $1.00 per share. 34,000 warrants were exercised in September 2014 and 567,000 warrants were expired as of December 31, 2014.

On April 3, 2014, the Company entered stock subscription agreement of 5,000 shares at $1.00 per share with 5,000 warrants to purchase 5,000 shares of common stock with an exercise price of $2.00 per share. These warrants expire 180 days after stock issuance date. The warrants were expired as of December 31, 2014.

On April 16, 2014, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 20,000 warrants to purchase 20,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire 180 days after stock issuance date. The warrants were expired as of December 31, 2014.

.

On July 7, and July 31, 2014, the Company entered stock subscription agreements of 50,000 shares and 20,000 shares at $1.00 per share with 50,000 and 20,000 warrants to purchase 50,000 and 20,000 shares of common stock with an exercise price of $2.00 per share. These warrants expire 360 days after stock issuance date. As of December 31, 2014, 50,000 and 20,000 warrants are not exercised or expired.

On August 22, 2014, the Company entered stock subscription agreement of 99,963 shares at $1.00 per share with 99,963 warrants to purchase 99,963 shares of common stock with an exercise price of $2.00 per share. These warrants expire 360 days after stock issuance date. As of December 31, 2014, 99,963 warrants are not exercised or expired.

On December 28, 2014, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 20,000 warrants to purchase 20,000 shares of common stock with an exercise price of $2.00 per share. These warrants expire 360 days after stock issuance date. As of December 31, 2014, 20,000 warrants are not exercised or expired

The following table summarizes all warrant activity for the years ended December 31, 2014 and 2013:

	Shares	Weighted-Average Exercise Price Per Share	Remaining term	Intrinsic value
Outstanding, December 31, 2013	100,000	1.00
Exercisable at December 31, 2013	100,000	1.00
Granted	1,423,112	1.16
Exercised	(34,000)	1.00
Expired	(1,299,149)	1.04	0.79 year	$ 0
Exercisable at December 31, 2014	189,963	2.00	0.79 year	$ 0

XML

8. Fair Value Measurements

12 Months Ended

Dec. 31, 2014

Notes to Financial Statements

8. Fair Value Measurements

8. Fair Value Measurements

On a recurring basis, we measure certain financial assets and liabilities based upon the fair value hierarchy as described in the Company’s significant accounting policies in Note 1. The following table presents information about the Company’s liabilities measured at fair value as of December 31, 2014

	Level 1	Level 2	Level 3	Fair Value at December 31, 2014
Liabilities
Derivative liability	-	$ 48,851	-	$                  48,851

	Level 1	Level 2	Level 3	Fair Value at December 31, 2013
Liabilities
Derivative liability	-	$ 349,940	-	$                  349,940

The fair value changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), relate solely to the derivative liability as follows:

Balance at December 31, 2013	349,940
Adjustment due to conversions	(141,294)
Adjustment due to exercise warrant	(18,700)
New warrant issued with stock	559,184
Fair value adjustment	(700,279)
Balance at December 31, 2014	$ 48,851

XML

10. Income Taxes

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

10. Income Taxes

10. Income Taxes

Deferred income taxes for 2014 and 2013 were provided for the temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities. The effects of temporary differences and carry-forwards at December 31, 2014 and 2013 are as follows:

Deferred tax assets:		December 31, 2014		December 31, 2013
Net operating loss carry-over	$	733,642	$	613,669
Derivative liability		(286,182)		(48,097)
Common stock issued for services rendered		3,848		3,848
Interest on derivative		242,693		151,827
Valuation allowance		(773,283)		(506,081)
Deferred tax assets per books	$	-	$	-

The income tax provision differs from the amount of income tax determined by applying the estimated U.S. federal and state income tax rates of 34 percent to pretax income from continuing operations for the year ended December 31, 2014 and 2013 due to the following:

		December 31, 2014		December 31, 2013
Income tax expense at statutory rate	$	(119,974)	$	(243,286)
Gain (loss) on derivative valuation		(238,095)		(21,839)
Common stock issued for services rendered		-		-
Interest on derivative		90,866		77,398
Valuation allowance		267,203		187,727
Income tax expense per books	$	-	$	-

As of December 31, 2014, the Company had net operating loss carry forwards for income purposes of approximately $733,643 ($613,669 as of December 31, 2013) that may be offset against future taxable income. The net operating loss carry-forwards expire through the year 2034. Current tax laws limit the amount of loss available to be offset against future taxable income when a substantial change in ownership occurs or a change in the nature of the business. Therefore, the amount available to offset future taxable income may be limited.

No tax benefit has been reported in the consolidated financial statements for the realization of loss carry-forwards, as the Company believes there is high probability that the carry-forwards will not be utilized in the foreseeable future.

XML

6. Convertible Debenture (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Notes to Financial Statements
Compound derivative	$ 267,253	$ 0
Interest expense	$ 0	$ 0

XML

1. Nature of Operations and Basis of Presentation (Policies)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Nature of Operations

Nature of Operations

Technology Applications International Corporation (“Technology”) was incorporated on October 14, 2009 under the laws of Florida. Rejuvel Int’l, Inc. and NueEarth, Inc., Technology’s wholly owned subsidiaries and Technology, collectively, are referred to here-in as the “Company”. The Company is engaged in developing market entry technology products and services into early and mainstream technology products and services. Through our subsidiaries, we are focused on developing and manufacturing a line of technologically advanced skin care products and providing environmental management solutions that use electron particle accelerator technology.

Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the accounts of Technology Applications International Corporation and its wholly owned subsidiaries, Rejuvel Int’l, Inc. and NueEarth, Inc. All significant inter-company accounts and transactions have been eliminated in consolidation.

Basis of Presentation and Going Concern Considerations

Basis of Presentation and Going Concern Considerations

The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) applicable to a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Realization values may be substantially different from carrying values as shown and these financial statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs. The Company’s ability to continue as a going concern is highly dependent upon management’s ability to increase near-term operating cash flows and obtain additional working capital through the issuance of debt and or equity.

Management intends to finance operating costs over the next twelve months with existing cash on hand, from the issuance of common shares, and additional related party borrowings. The Company's future operations are dependent upon external funding and its ability to execute its business plan, realize sales and control expenses. Management believes that sufficient funding will be available from additional borrowings and private placements to meet its business objectives including anticipated cash needs for working capital, for a reasonable period of time. However, there can be no assurance that the Company will be able to obtain sufficient funds to continue the development of its business operation, or if obtained, upon terms favorable to the Company. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

Development Stage Risk

Development Stage Risk

Since its inception, the Company has been dependent upon the receipt of capital investment to fund its operating activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plans will be successfully executed. The Company’s ability to execute its business plans is dependent on its ability to obtain additional debt and equity financing and achieving a profitable level of operations. There can be no assurance that sufficient financing will be obtained or that we will achieve a profitable level of operations.

Use of Estimates

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and their reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Risks and Uncertainties

Risks and Uncertainties

The Company is subject to substantial risks from, among other things, intense competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements and limited operating history.

Contingencies

Contingencies

Certain conditions may exist as of the date the consolidated financial statements are issued which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company's management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company's legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be provided for in the Company's consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.

There were no contingencies which could be evaluated at December 31, 2014.

Cash and Cash Equivalents

Cash and Cash Equivalents

Cash and cash equivalents consist of highly-liquid investments with a maturity of less than three months when purchased.

Inventories

Inventories

Inventories are stated at the lower of cost or market value using the FIFO (first-in, first-out) method.

The Company maintains a reserve for the inventory based on the estimated losses that result from inventory that becomes obsolete or for which the Company has excess inventory levels as of period end. In determining these estimates, the Company performs an analysis on current demand and usage for each inventory item over historical time periods. Based on that analysis, the Company reserves a percentage of the inventory amount within each time period based on historical demand and usage patterns of specific items in inventory.

Machinery and Equipment

Machinery and Equipment

Machinery and equipment are recorded at cost. Expenditures for maintenance and repairs are charged to earnings as incurred whereas additions, renewals and betterments are capitalized. When machinery and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of machinery and equipment is provided using the straight-line method over the assets estimated useful lives of approximately 5 to 7 years. Leasehold improvements, if any, are amortized on a straight-line basis over the term of the lease or the estimated useful lives, whichever is shorter.

Intangible Assets

Intangible Assets

Intangible consist of trademarks and licenses (Trademarks have a 20 year life and licenses have a 7 year life.) which are being amortized using the straight-line method over their estimated period of benefit. We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. All of our intangible assets are subject to amortization. No impairments of intangible assets have been identified during any of the periods presented.

2015	2,252
2016	2,252
2017	2,252
2018	2,252
2019	2,252
Thereafter	4,599

Amortization expense for the years ended December 31, 2014 and 2013 was $1,082 and $109, respectively.

Long-Lived Assets

Long-Lived Assets

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of definite-lived assets to be held and used is measured by comparison of the carrying amount of an asset to future undiscounted cash flow expected to be generated by the asset. If such assets are impaired, the impairment is recognized as the amount by which the carrying amount exceeds the estimated future cash flows. Assets to be sold are reported at the lower of the carrying amount or the fair value less costs to sell. Indefinite-lived assets are tested for impairment annually or when impairment is suspected by a comparison of the carrying amount of the asset to the net present value of future cash flows expected to be generated by the asset. There were no impaired assets at December 31, 2014.

Revenue Recognition

Revenue Recognition

The Company's revenue recognition policies are in compliance with Staff Accounting Bulletin No. 104, "Revenue Recognition." Sales revenue which has been insignificant to December 31, 2014, is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue.

Research and Development Costs

Research and Development Costs

Research and development costs, which relate primarily to the development, design and testing of products, are expensed as incurred. Such costs were approximately $6,563 and $8,319 for the years ended December 31, 2014 and 2013, respectively.

Advertising and Marketing

Advertising and Marketing

Advertising and marketing expenses are expensed as incurred. Expense recorded for the years ended December 31, 2014 and 2013 were approximately $102,886 and $86,442, respectively.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

In accordance with FASB ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

In determining fair value, the Company uses various valuation approaches. In accordance with GAAP, a fair value hierarchy for inputs is used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the inputs market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels based on the inputs as follows:

· Level 1 — Inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.

· Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.

· Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

As of December 31, 2014 and December 31, 2013, the derivative liabilities amounted to $48,851 and $349,940, respectively. In accordance with the accounting standards, the Company determined that the carrying value of these derivatives approximated the fair value using the level 2 inputs.

Derivative Financial Instruments

Derivative Financial Instruments

Derivative financial instruments, as defined in Financial Accounting Standards, consist of financial instruments or other contracts that contain a notional amount and one or more underlying components (e.g. interest rate, security price or other variable), require no initial net investment and permit net settlement. Derivative financial instruments may be free-standing or embedded in other financial instruments. Further, derivative financial instruments are initially, and subsequently, measured at fair value and recorded as liabilities or, in rare instances, assets. The Company generally does not use derivative financial instruments to hedge exposures to cash-flow or market or foreign-currency risks. However, the Company has entered into various types of financing arrangements to fund its business capital requirements, including convertible debt and other financial instruments indexed to the Company’s own stock. These contracts require careful evaluation to determine whether derivative features embedded in host contracts require bifurcation and fair value measurement or, in the case of freestanding derivatives (principally warrants) whether certain conditions for equity classification have been achieved. In instances where derivative financial instruments require liability classification, the Company is required to initially, and subsequently, measure such instruments at fair value. Accordingly, the Company adjusts the fair value of these derivative components at each reporting period through a charge to income until such time as the instruments acquire classification in stockholders’ equity. See Note 8 for additional information.

As previously stated, derivative financial instruments are initially recorded at fair value and subsequently adjusted to fair value at the close of each reporting period. The Company estimates fair values of derivative financial instruments using various techniques (and combinations thereof) that are considered to be consistent with the objective measuring fair values. In selecting the appropriate technique, management considers, among other factors, the nature of the instrument, the market risks that it embodies and the expected means of settlement. For less complex derivative instruments, such as free-standing warrants, the Company uses the Black-Scholes-Merton option valuation technique because it embodies all of the requisite assumptions (including trading volatility, dividend yield, estimated terms and risk free rates) necessary to fair value these instruments. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are highly volatile and sensitive to changes in the trading market price of our common stock, which has a high-historical volatility. Since derivative financial instruments are initially, and subsequently, carried at fair values, our income (loss) will reflect the volatility in these estimate and assumption changes.

Income Taxes

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income during the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses. No interest expense or penalties have been assessed as of, and for the years ended, December 31, 2014 and 2013.

Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash accounts. The Company places its cash in what it believes to be credit-worthy financial institutions. Accounts at each financial institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At December 31, 2014 and 2013, the Company’s cash balances did not exceed federally insured limits.

Earnings (Loss) Per Common Share

Earnings (Loss) Per Common Share

The Company computes earnings per share in accordance with ASC 260, Earnings Per Share (“ASC 260”). Basic earnings (loss) per share are computed by dividing the net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted earnings per share adjusts basic earnings per share for the effects of stock options and other potentially dilutive financial instruments, only in the periods in which the effects are dilutive.

For the years ended December 31, 2014 and 2013, there were warrants to purchase 189,963 shares and 100,000 shares, respectively, of common stock that were excluded from the diluted earnings per share computation because the impact of the assumed exercise of such warrants would have been anti-dilutive, based on the fact that their exercise price exceeded the market price of the common stock as of December 31, 2014 and 2013.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

On June 10, 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-10 (ASU 2014-10), Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. ASU 2014-10 eliminates the requirement to present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclosure the risks and uncertainties related to their activities. ASU 2014-10 also eliminates an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The presentation and disclosure requirements in Topic 915 will no longer be required for interim and annual reporting periods beginning after December 15, 2014, and the revised consolidation standards will take effect in annual periods beginning after December 15, 2015. Early adoption is permitted. The Company adopted the provisions of ASU 2014-10 effective for its financial statements for the interim period ended September 30, 2014. The adoption of ASU 2014-10 did not have any effect on the Company’s financial statement presentation or disclosures.

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position or results of operations upon adoption.

XML

9. Derivative Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2014

Investments, All Other Investments [Abstract]

Valuation of derivative liability

Risk-free interest rate	0.25%
Estimated volatility	186%
Dividend rate	None
Estimated term in years	0.5-1.1

XML

x. Commitment (Details Narrative)	0 Months Ended	12 Months Ended
	Sep. 11, 2014	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Rental Lease commitment	26 months	26 months

XML

9. Derivative Financial Instruments - Black-Sholes Assumptions (Details)	12 Months Ended
	Dec. 31, 2014
Investments, All Other Investments [Abstract]
Risk free interest rate	0.25%
Estimated volatility	186.00%
Dividend rate	0.00%
Estimated term in years, max	6 months
Estimated term in years, min	1 year 1 month

XML

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (USD $)	Common Shares	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 31, 2012	$ 117,248	$ 505,220	$ (1,089,363)	$ (466,895)
Beginning Balance, Shares at Dec. 31, 2012	117,248,000
Shares issued for convertible notes converted, Shares	100,000
Shares issued for convertible notes converted, Amount	100	80,979		81,079
Net loss			(715,546)	(715,546)
Ending Balance, amount at Dec. 31, 2013	117,348	586,199	(1,804,909)	(1,101,362)
Ending Balance, shares at Dec. 31, 2013	117,348,000
Shares issued for cash, Shares	815,963
Shares issued for cash, Amount	816	200,619		201,435
Shares issued from exercising of warrants, Shares	34,000
Shares issued from exercising of warrants, Amount	34	52,666		52,700
Shares issued for convertible notes converted, Shares	607,149
Shares issued for convertible notes converted, Amount	607	446,718		447,325
Shares purchase back by notes payable issuance, Shares	(67,666,619)
Shares purchase back by notes payable issuance, Amount	(67,667)	(12,000)		(79,667)
Shares purchase back by cash, Shares	(1,000,000)
Shares purchase back by cash, Amount	(1,000)			(1,000)
Net loss			(352,865)	(352,865)
Ending Balance, amount at Dec. 31, 2014	$ 50,138	$ 1,274,202	$ (2,157,774)	$ (833,434)
Ending Balance, shares at Dec. 31, 2014	50,138,493

XML

4. Inventories

12 Months Ended

Dec. 31, 2014

Inventory Disclosure [Abstract]

4. Inventories

4. Inventories

Inventories, as of December 31, 2014 and 2013, consisted of the following:

	December 31,
		2014		2013
Raw materials	$	-	$	-
Work-in-process		-		-
Finished goods		4,831		70,862
Total Inventories, net	$	4,831	$	70,862

No reserves for inventory have been deemed necessary at December 31, 2014 and 2013.

XML

10. Income Taxes (Tables)

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Deferred Tax Assets

Deferred tax assets:		December 31, 2014		December 31, 2013
Net operating loss carry-over	$	733,642	$	613,669
Derivative liability		(286,182)		(48,097)
Common stock issued for services rendered		3,848		3,848
Interest on derivative		242,693		151,827
Valuation allowance		(773,283)		(506,081)
Deferred tax assets per books	$	-	$	-

Income Tax Provision

		December 31, 2014		December 31, 2013
Income tax expense at statutory rate	$	(119,974)	$	(243,286)
Gain (loss) on derivative valuation		(238,095)		(21,839)
Common stock issued for services rendered		-		-
Interest on derivative		90,866		77,398
Valuation allowance		267,203		187,727
Income tax expense per books	$	-	$	-

XML

8. License Agreement - Derivative Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Derivative liability	$ 48,851	$ 349,940
Level 1
Derivative liability	0	0
Level 2
Derivative liability	48,851	349,940
Level 3
Derivative liability	0	0
Fair Value
Derivative liability	$ 48,851	$ 349,940

XML

x. Commitment

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

9. Commitment

12. Significant Agreement

On September 30, 2013, the Company and its wholly-owned subsidiary Rejuvel Int’l, Inc., Florida corporations (the “Company”) entered into a partially exclusive Co-License Agreement (the “License Agreement”) by and amongst the National Aeronautics and Space Administration, an agency of the United States (“N.A.S.A.”) and the Administrators of the Tulane Educational Fund (“Tulane University”) for the use of U.S. Patent No. 6,730,498 B1, an invention entitled “Production of Functional Proteins: Balance of Shear Stress and Gravity,” which was issued on May 4, 2004 (the “Patent”). The company currently uses the Patent process to develop our anti-aging skin creams and shampoos. The License Agreement permits the Company to use the Patent as well as the name N.A.S.A., with its products, as per the terms of the License Agreement.

On July 25, 2014, Technology Applications International Corporation and its wholly-owned subsidiary Rejuvel Int’l, Inc., Florida corporations (the “Company”) entered into an exclusive License Agreement (the “License Agreement”) by and between the National Aeronautics and Space Administration, an agency of the United States (“N.A.S.A.”) for the use of U.S. Patent No.’s 6,485,963 B1, an invention entitled “Growth Stimulation Of Biological Cells and Tissue By Electromagnetic Fields and Uses Thereof” which was filed on June 2, 2000, and U.S. Patent No. 6,673,597 B2, for an invention entitled “Growth Stimulation of Biological Cells and Tissue By Electromagnetic Fields and Uses Thereof, which was filed on February 28, 2001 (the “Patents”). We currently use the Patents process to develop our anti-aging skin creams and shampoos. The License Agreement permits the Company to use the Patents as well as the name N.A.S.A., with its products, as per the terms of the License Agreement.

In consideration of the grant of the License Agreement, the Company will pay a 3% royalty to N.A.S.A. on the gross sales of any royalty-base products. The License agreement further requires the Company to remit to N.A.S.A. a non-refundable license fee in the amount of Fifteen Thousand Dollars ($15,000) upon the execution of the License Agreement and then another Fifteen Thousand Dollars ($15,000) is due six months after the license commencement date. The Company also agrees to pay N.A.S.A. a minimum royalty of Fifteen Thousand Dollars ($15,000), at the end of each accounting period (“Accounting Period”). The Accounting Period shall begin at the end of the second Accounting period of the License Agreement and each Accounting period thereafter.

The License Agreement requires that the Company achieve a practical application of the Patent within eighteen (18) months from the commencement date of the License Agreement. In accordance with the appendix to the License Agreement; wherein it states that by August 2014, the Company shall have tested the product to meet federal, state and international regulations of its skin cream products, by October 2014, the Company shall have packaged and filled five products and by December 2014, the Company shall have Domestic and International distribution of five products. Once a practical application is achieved the term of the agreement shall be equal to the unexpired term of the last patent to be in effect of the patent(s) encompassed under the Patents. The Company further agrees that any products using the Patents process shall be substantially manufactured in the United States. As of the Date of this filing all milestones associated with the License Agreement have been completed on time and to the satisfaction of the License Agreement Parties.

On October 4, 2013, the Company terminated its distribution agreement (“Distribution Agreement”) by and between the Company and Regenetech, Inc., a Texas corporation, pursuant to the termination clauses contained within the Distribution Agreement. Regenetech, Inc., was in a material breach of contract of the Distribution Agreement, because Regenetech, Inc., failed to upkeep its license requirements with N.A.S.A. and the Tulane University in order to maintain the license in good standing. Due to the material breach of contract by Regenetech, Inc., the termination of the Distribution Agreement does not contain any early termination penalties to the Company.